Podcasts about nhs england

Brought to you by the English Programme. Featuring news, politics, popular culture, celebrity trivia, quizzes, book readings, and a whole host of fun.Support Our Rescue Cats | Our Blog | Get New Episodes By Email | Rumble | X | YouTube | NewsK365 on Spreaker | Get New Blog Posts By Email | Throne Wishlist |

Brought to you by the English Programme. Featuring news, politics, popular culture, celebrity trivia, quizzes, book readings, and a whole host of fun.Support Our Rescue Cats | Our Blog | Get New Episodes By Email | Rumble | X | YouTube | NewsK365 on Spreaker | Get New Blog Posts By Email | Throne Wishlist |

Brought to you by the English Programme. Featuring news, politics, popular culture, celebrity trivia, quizzes, book readings, and a whole host of fun.Support Our Rescue Cats | Our Blog | Get New Episodes By Email | Rumble | X | YouTube | NewsK365 on Spreaker | Get New Blog Posts By Email | Throne Wishlist |

Brought to you by the English Programme. Featuring news, politics, popular culture, celebrity trivia, quizzes, book readings, and a whole host of fun.Support Our Rescue Cats | Our Blog | Get New Episodes By Email | Rumble | X | YouTube | NewsK365 on Spreaker | Get New Blog Posts By Email | Throne Wishlist |

In this episode we explore how three advanced practitioners, alongside the Advanced Practice Lead from Great Western Hospitals NHS Foundation Trust have used their leadership, research and education pillars. We discuss how they have improved patient care and implemented service changes, and the impact this has had within their service but also across the wider organisation. Host: Lou Buckle, NHS England, South West, Advanced Practice Education and Development Specialist Lead. Guests:Lucy Moxham, Advanced Practice Corporate Professional Lead & Lead Advanced Practitioner in Acute Medicine, Great Western Hospitals NHS Foundation Trust;Dana Rankin, Advanced Practitioner, Great Western Hospitals NHS Foundation Trust; Joanna Mudge, Advanced Practitioner, Great Western Hospitals NHS Foundation Trust; Stacey Dodson, Advanced Practitioner, Great Western Hospitals NHS Foundation Trust

At EBPOM 2026 live from the British Library in London, Joff Lacy and Imogen Fecher-Jones speak with Malcolm West and Tim Baker, clinical co-leads for the National Clinical Audit of Perioperative Care (NCAPC), an NHS England mandated and HQIP-funded initiative managed by the Royal College of Anaesthetists to audit major elective surgery in England and publicly funded Jersey. They outline the audit's denominator (major surgery with anaesthetist involvement and >24-hour stay), year-one focus cohorts (thoracic, major gynaecology, major hip/knee orthopaedics, and lower GI/colorectal surgery), and aims to improve data quality and reduce unwarranted variation. The team describes a rapid modified Delphi process involving 200+ professionals and 70+ patients to define core metrics, highlights plans to automate data collection via hospital electronic records, and explains local roles, an organisational survey, and the goal of ongoing expansion and long-term delivery. FOR MORE ON EBPOM IRELAND GO HERE: www.ebpom.org

genedrive PLC (AIM:GDR) CEO Dr Gino Miele spoke with Proactive's Stephen Gunnion about the diagnostic company's progress in rapid point-of-care genetic testing, growing NHS adoption and international expansion plans. Miele explained that Manchester-based genedrive has developed two CE-IVD-approved, NICE-recommended tests to help clinicians make safer prescribing decisions in emergency and acute care. The MT-RNR1 test identifies newborns at risk of irreversible hearing loss from aminoglycoside antibiotics, while the CYP2C19 test identifies stroke patients unlikely to respond well to the antiplatelet drug clopidogrel. On MT-RNR1, Miele highlighted completion of patient recruitment for the PALOH UK programme, covering more than 6,000 babies across 14 hospitals in all four UK nations, with clinical analysis under way and publication expected next month ahead of further NICE guidance in July 2027. "This will be a really important commercial catalyst for the business, alongside NHS England procurement routes as well," he said. He discussed international ambitions, including a memorandum of understanding with Saudi Arabia's Ministry of Health, routine clinical use at the National Guard hospital there, implementation at Erasmus MC in the Netherlands, and plans around FDA routes in the US. Miele also highlighted genedrive's collaboration with Thermo Fisher to develop a laboratory-format version of the CYP2C19 test, complementing its existing point-of-care offering. Longer term, genedrive is targeting further international expansion, additional clinical indications, and recurring consumables revenue as its tests become embedded in routine care pathways. Visit Proactive's YouTube channel for more interviews and market updates. Give the video a like, subscribe to the channel and enable notifications so you don't miss future content. Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy #genedrive #GDR #GeneticTesting #Pharmacogenetics #Diagnostics #PointOfCareTesting #NHS #NICE #MTRNR1 #CYP2C19 #Stroke #Healthcare #MedTech #MolecularDiagnostics #PersonalisedMedicine #ThermoFisher #Investing #Proactive

One doctor dies by suicide every three weeks, according to figures from the British Medical Association.In 2021, Dr Lalith Wijedoru left his role as consultant paediatrician in emergency medicine, to focus on supporting workforce health and wellbeing, including those working in healthcare. Given rare access to a wellbeing and recovery retreat, we hear emotional testimonies from the four groups of doctors at greatest risk of suicide - General Practitioners, anaesthetists, surgeons and psychiatrists.Their stories - of workplace bullying, isolation, fatigue and fear of patient complaints - suggest a system in which doctors are made to feel like machines, rather than human beings. The concept of 'moral injury' is also a factor - where a doctor is unable to provide the care they wish to give to their patient, due to lack of resources or system breakdown. Many doctors we hear from say they feel intense internalised pressure to do better - to work harder, and to never complain at worsening conditions. All have suffered from fear of failure, and the lack of the opportunity to decompress after traumatic events in the workplace. These stories take us to the heart of issues being faced by many or most NHS professionals - and by the ‘system' more generally.For Lalith, this sharing of difficult stories is an important pathway to recovery, even a life-saving intervention.Lalith is spurred on to talk to those who seek to help and support doctors, from charities like Doctors in Distress, founded by the brother of a doctor who died by suicide, as well as those who are studying the problem of why - and how many - doctors are dying by suicide. Worryingly, there are gaps in available data, because statistics are drawn from coroners' Preventable Death reports. In England, these are a matter for each individual coroner to decide on, so death by suicide is not uniformly recorded. Having laid many of these problems bare, what hope is there of realistic change and improvement? Presenter: Dr Lalith WijedoruProducer: Amanda HargreavesSound design: Joel CoxLocation recordings: Jon CalverExecutive producer: Dave HowardA Bespoken Media Scotland production for BBC Radio 4 This programme contains reference to suicide. If you've been affected by issues raised in this programme, you can find out more about organisations that can help by going to www.bbc.co.uk/actionline.There are also specific resources available to doctors and healthcare workers - some links to these below.NHS Practitioner Health https://www.practitionerhealth.nhs.uk/British Medical Association (confidential helpline with counselling and peer support for doctors and medical students https://www.bma.org.uk/advice-and-support/your-wellbeing/wellbeing-support-services/counselling-and-peer-support-servicesDepartment of Health and Social Care (text message service - support available for workers in NHS England) https://www.england.nhs.uk/supporting-our-nhs-people/support-now/Doctors In Distress https://doctors-in-distress.org.uk/You Okay Doc? https://youokaydoc.org.uk/NHS Employers (Suicide Prevention/Postvention Toolkit) https://www.england.nhs.uk/publication/working-together-to-prevent-suicide-in-the-nhs

Where are neighbourhoods taking general practice, and what does this mean for Primary Care Networks? In this episode, Ben is joined by Ceri Chaplin, Managing Partner at Hereford Medical Group, and Robert McCartney, Partner at Hempsons, to discuss the latest NHS England neighbourhood proposals and what they could mean for practices. They explore the changing role of PCNs, funding and locally enhanced services, governance, relationships between practices, and why now is the time for practices to prepare for what comes next. What exactly is a neighbourhood? (00:27) How different areas are approaching neighbourhoods (02:13) What does the NHS England consultation tell us? (04:14) Funding, contracts and potential risks for practices (05:15) Are neighbourhoods simply the next stage of PCNs? (07:05) What could changes mean for practices and PCN funding? (09:07) What should practices be doing now? (15:20) Governance, incorporation and preparing for new contracts (16:33) The challenge of difficult PCN relationships (18:00) Why practices need to act now (20:20) Should practices respond to the consultation? (20:43) The opportunities neighbourhood working could bring (21:32) Shifting care into primary and community care (23:02) For all enquiries about the Ockham podcast, please contact Ben Gowland here.

In this episode of Behind the Genes, we explore how personalised cancer vaccines are being developed, and how genomics and AI could help make these treatments more precise.  Our host, Florence Cornish is joined by:  Dr Victoria Goss, Associate Professor of Early Diagnosis and Translational Research at Southampton Clinical Trials Unit and head of the Southampton Clinical Trials Unit Cancer Vaccine Launchpad team  Professor Lennard Lee, Associate professor at the University of Oxford, Consultant Medical Oncologist, NHS  Ali Richards, a participant who took part in a cancer vaccine clinical trial  Together they discuss how cancer vaccines train the immune system to recognise cancer, how genomic information can help identify the unique features of an individual's tumour, and how AI could help researchers analyse genomic data and accelerate the development of new cancer vaccines.   “The reason I said yes was because my treatment really was punishing. It was so many side effects to it. The cancer never made me feel sick, but the treatment made me really sick. So I said yes because I just wanted to help other people not have to go through what I went through.”    Transcript [00:00:00] Florence: What if a vaccine could help treat cancer? Hello and welcome to Behind the Genes, the podcast that brings you the stories, research, and innovations shaping the future of genomic healthcare. Today, we're going to be talking about cancer vaccines, how they're being developed with the help of AI, what role genomics has to play, and what it could mean for patients.  [00:00:23] Florence: I'm Florence Cornish, and joining me today we have Dr Victoria Goss, who leads cancer vaccine research at Southampton Clinical Trials Unit; we have Professor Lennard Lee, who is a medical oncologist and Associate Professor at the University of Oxford; and Ali Richards, who took part in the Southampton Cancer Vaccine Programme.  [00:00:45] Florence: I think before we get into cancer vaccines specifically, it might be good to start with the basics. So vaccines are something most of us have heard of and probably experienced as well, but we don't always necessarily understand how they work. So Lennard, can I come to you to explain what a vaccine actually is, how it works with our immune system, maybe at the most basic level for those who might not have a scientific background?  [00:01:19] Lennard: Thanks, Florence. What's a vaccine? Very, very simply, something that protects your body from disease. We've had a few when we were younger, like which protects you against meningitis or hepatitis or different types of infections that can affect children.  [00:01:36] Lennard: And it really does show that your immune system is really powerful. Every day, it looks around trying to work out what's there which shouldn't be there and takes care of it. And ideally, your immune system just works in the background without causing any problems. And so what a vaccine does is it really helps the body understand something that's abnormal.  [00:01:55] Lennard: And the vision here is that you can use this technology to hopefully patrol against cancer, because half the people out there will never get cancer. They are the maybe the lucky ones or maybe the ones with a good immune response. And so a vaccine is basically giving your immune system a wanted poster:  [00:02:11] Lennard: "This is what threat looks like. This is what you need to control".   [00:02:16] Florence: And I think you mentioned some great examples there. There are lots of common examples of vaccines people might have heard of. I think maybe the flu vaccine is probably a common one that people are thinking about in the wintertime. I think another one is maybe the HPV vaccine.  [00:02:29] Florence: Lennard, could you explain a bit more to our listeners about the HPV vaccine? What it is, how it works? I think people often think of it as a type of cancer vaccine, but actually it's targeting a virus. Is that right?   [00:02:41] Lennard: Yeah, that's correct. So this is now a vaccine which has been rolled out across the NHS, and it's actually worked really well to get rid of a few cancer types, which is incredible.  [00:02:51] Lennard: And why is that important? Well, cancer can be caused by many, many different things. Sometimes it's because you've done things like smoking or weight plays a role or just bad luck or the genes that you've inherited. But some cancer types are caused by viruses. And so many people nowadays are getting the HPV vaccine to stop cancer types like cervical cancer, hopefully head and neck cancer, and many of the rarer cancer types.  [00:03:21] Lennard: And so again, what you're doing here is you're taking the immune response, telling it the body shouldn't get this virus and hopefully prevent some of the bad consequence of getting this viral infection, like cancers.   [00:03:33] Florence: Thank you. That's really helpful to understand. So we've talked about how vaccines can be used to treat viruses, and I think most of us, when we hear the word ‘vaccine', we probably do associate it with something that stops us from getting ill.  [00:03:46] Florence: Victoria, could you tell us about how vaccines could be used to treat cancer?   [00:03:50] Victoria: Yeah, absolutely, and it is great to be here today. Thank you. So Lennard's already sort of spoken about preventative vaccines, and when we think about cancer vaccines, we're thinking about therapeutic vaccines. So we're thinking about training the immune system to recognise the cancer as something that needs to be dealt with because cancer is really tricky because it's our own cells that have gone wrong, if you like.  [00:04:16] Victoria: But that means it also is very good at evading those signals which tell the immune system that it needs to be cleared. So the analogy that Lennard has already given of a cancer vaccine sort of creating a wanted poster sort of builds on an analogy from one of your previous podcasts where they described the immune system as like the police almost trying to catch criminals, which are the cancer cells.  [00:04:41] Victoria: And the cancer vaccine analogy builds on that. So you've created a wanted poster which is training and giving the police more information about what those cancer cells look like. And then when we think about building on that with sort of personalised cancer vaccines, which is an incredibly exciting step when we think about the development of how cancer vaccines can be used, sort of really individualised therapy going forward, that wanted poster gets even more specific.  [00:05:07] Victoria: It's almost like giving a phone number or an address for that specific cancer type that is very specific to that patient. So the therapeutic vaccine is, is targeting the immune system. It's training our immune system to recognise the cancer as something that needs to be dealt with.   [00:05:26] Florence: It's funny you mentioned that analogy because I was just about to point listeners to that episode. If anyone wants to learn more about cancer vaccines specifically, you can check out our previous Genomics 101 podcast episode called ‘What Are Cancer Vaccines?' So Ali, I think I'd love to bring you in at this point because you have experienced this from the patient side of things.  [00:05:49] Florence: Could you tell us a little bit about your journey, your cancer diagnosis and treatment, and maybe more about the clinical trial you were part of, if you feel comfortable sharing that?   [00:05:57] Ali: Yeah, sure. Hi, Florence. It was Christmas 2015, and I felt a lump in my neck. And maybe because I'm a woman and we're always taught to treat lumps seriously, in the January I made an appointment with the GP, and she very quickly fast-tracked me through to the hospital.  [00:06:19] Ali: And January 2016, I got a diagnosis. It was a tumour on the base of my tongue at the left, and I was told it was caused by a variation of the HPV virus. So yeah, that was all a bit of a shock. I was shocked and I was scared, but I was also really angry because I look after myself. I eat well, all those things.  [00:06:45] Ali: It's just bad luck that it was a virus that my body couldn't deal with. I just, I felt guilty as well because of what I was gonna put the family through. So I had various scans and tests. I had an operation to remove my tonsils, although we soon discovered there weren't any left anyway. And they took a biopsy, which I didn't know at the time, but turned out to be important later on for the trial.  [00:07:15] Ali: Then I had to have a whole load of prep beforehand because of the impact of the treatment. So I had to have restorative dentistry, audiology tests. I had a PEG fitted, that's a feeding tube, in my stomach, and I thought, "Surely it's not going to be this bad." But that PEG, that feeding tube was a blessing in the end.  [00:07:40] Ali: And I had a mask made, and the mask fits you and basically pins you down to the radiotherapy table so you don't move when... because it's very precisely targeted at your tumour. So yeah, I went on to have five sessions of chemo, which felt quite easy. The radiotherapy was the really, really tough part. I had, uh, seven weeks of it, 35 sessions.  [00:08:08] Ali: So that was, yeah, that was a challenge.   [00:08:11] Florence: Thank you, Ali. Thank you for sharing that. I think it's always really valuable to get that patient perspective when we're talking about things like this. Lennard, I wanted to come back to you now to talk about the different types of vaccines that exist and which ones are being used specifically in the treatment of cancer.  [00:08:30] Lennard: Um, thanks, Florence. And Ali, are you 10 years now down the line since your diagnosis?   [00:08:34] Ali: Yeah, it feels good.   [00:08:37] Lennard: Congratulations.   [00:08:38] Ali: Yeah, yeah. It feels good. I really valued the follow-up checks that I had, both from my oncologist, but also I got some through the trial, and it really helped restore some confidence in myself and my body to deal with things and to be able to move on as well.  [00:08:56] Lennard: Oh, well done. That's fantastic because you telling us that story just really brings it to life about how scary this can be and also the fact that you had to go through all those sessions, thirty-five sessions and, um, and now you're 10 years down the line and still talking and giving hope-   [00:09:11] Ali: Yeah ...   [00:09:11] Lennard: that new technology still comes, so thanks, Ali.  [00:09:13] Ali: That's a pleasure.   [00:09:14] Lennard: Um, yeah, so Frances, this is what's really exciting. What types of vaccines are there? Well, first thing to say is that we're really good in this country about vaccine research. If you look around the world, what are we good at? Well, everyone knows that we developed the pandemic vaccine, and actually that technology is something that we can control.  [00:09:31] Lennard: We're world leaders at. It's quite cheap technology, and it's something that we are really good at bringing to patients. And Ali's our testament where she got on the trial, she helped test it and really pioneered new ways of research. So what types of vaccines are there? Well, I think we talked to the first bit where Victoria taught us that some of them can treat cancers and some of them can maybe prevent cancers.  [00:09:53] Lennard: And the HPV's one which is maybe be able to do both one day, which is brilliant. What would like... what else do people know about? Well, people might know that there are different types of technologies. So if we think back a few years now, back to 2020, there are some which are viral-based, and some which are mRNA based.  [00:10:12] Lennard: Both of these were new technologies which the whole population of the world came together to create and some of them are peptide-based. So there's probably three different types here. The protein ones or peptide one, which you always had, and then in the last five years, it's an incredible time to be alive, where new vaccine technology comes through, it's more effective and safer.  [00:10:32] Lennard: These are the viral ones and mRNA ones, and everyone's now pursuing all of these to try and make sure that we can maybe treat cancer in future.   [00:10:41] Florence: Can I possibly pick your brain a little bit more about the mRNA ones specifically? I think as you mentioned, lots of people might have heard of those during COVID.  [00:10:50] Florence: Could you maybe explain a little bit more about those and how they work?   [00:10:53] Lennard: Yeah. So this is going to take us all the way back to GCE biology now. If you remember - and we are Genomics England, so we, we got to work out why genomics is important, and we'll probably get to this. But remember, genes make RNA, which then makes protein.  [00:11:11] Lennard: And so if you're trying to reprogramme the immune response, you could give your body a protein, the back end of it. You can maybe give it an RNA, which is a blueprint too. And so what an mRNA vaccine is, it's a way of giving the blueprint or the instructions to the body of what to recognise, what the cancer looks like, um, um, or what the virus looks like, and target it.  [00:11:32] Lennard: If you want the analogy, well, for those people who had the pandemic vaccines, the ones which was mRNA based was, uh, the Pfizer one, and that worked really, really well. Cheap to make, easy to produce, and, uh, it's just a jab. And so people are now exploring that for cancer treatment now. Take new technology, which has only been developed five years ago, technology, which is just a blueprint, cheap to make, easy to update, and now we're targeting cancer.  [00:11:59] Lennard: Um, so that's basically what an mRNA vaccine is, giving the body the blueprint or the instruction of what a cancer looks like and trying to target that cancer.   [00:12:08] Florence: And you kind of alluded to it a little bit in your answer, but, um, it would be good to know more about where genomics comes into all of this. You know, why is it such an important part of developing vaccines?  [00:12:18] Lennard: And that's a great question, and really comes back to our second strengths, which is that we're really good at vaccine research, and yet we are also world leaders at genomic research. It's a really exciting time because, um, when Victoria and me and Ally at school, we would-- we, we learnt about that race to sequence the first human genome.  [00:12:38] Lennard: It was really exciting because for the first time, we can see every single genetic base in every human, and that used to cost billions of pounds to do that, and it would take many months or years to do that Fast-forward a few years, and then now Genomics England delivered the next success for humanity.  [00:12:57] Lennard: I think it was about 2015 to 2017 where they, they did 100,000 Genome Project, where the UK led the world in sequencing 100,000 people, including people with cancer, to try and understand what caused their cancer, what the risk factors are. And why is that relevant now? Well, it's because if you know what a cancer looks like, then you know what the abnormality is, well, then you can vaccinate against it.  [00:13:22] Lennard: So we've now gone from this amazing arc of discovery here, where when we were at school, we worked out what the human genome looks like. We can sequence it end to end and see in all its detail. Then a, an amazing organisation came out the ground called Genomic England, which shows that you can run it in the NHS.  [00:13:39] Lennard: 100,000 people could do it. And now we're making the next big jump now, which is it's not just going to give you a diagnosis, but maybe becomes a drug and a vaccine in future. And actually, probably it already has because Ali's that example, a success example of it happening.   [00:13:54] Florence: Yeah, I wanted to actually ask you about that, Ali.  [00:13:56] Florence: So just as you were saying, Lennard, it kind of... The cancer vaccine sounds quite futuristic, but as you said, it's, it's sort of already happening. So Ali, do you remember kind of how you first heard about the cancer vaccine trial?   [00:14:11] Ali: Yeah. I had a bit of an unfortunate time because after all that radio and chemo, my cancer still hadn't gone, and I had to have an operation to remove lymph nodes.  [00:14:22] Ali: But my oncologist at Poole Hospital, who's a fantastic woman, she had been involved, unknown to me, in the some of the thinking behind the trial, and particularly that she could recruit people because they were sat in her office. So she asked me if I'd like to take part, and without knowing anything, I said yes.  [00:14:49] Ali: And the reason I said yes was because my treatment really was punishing. It was so many side effects to it. The cancer never made me feel sick, but the treatment made me really sick. So I said yes because I just wanted to help other people not have to go through what I went through. I didn't really understand it, if I'm perfectly honest.  [00:15:16] Ali: I didn't really know what was going on, but then I'm not, you know, a super brain like Lennard and Victoria. I knew that I just wanted to do something to help people going forward, not having to deal with the same. So yeah, I put my hand up and there I was on the trial.   [00:15:37] Florence: So you mentioned there the, the really horrible side effects that you got from your original treatment. Did you have, um, what was your experience with side effects with the vaccine? Was it similar? Was it different?   [00:15:47] Ali: Oh, no, the, the vaccine was like a holiday compared to the treatment. Absolutely. At, at worst, in the first few treatments, you felt a bit like you had a cold, bad cold coming on, maybe slightly flu-y, but you took, you were given Ibuprofen at the same time as you had the vaccine.  [00:16:10] Ali: So no, it, the treatment with the vaccine was an absolute breeze. Which is kind of like, yes, this is what I want for people. You know, not, not the radiotherapy, not the chemo. So yeah, it was, it was really very easy by comparison.   [00:16:29] Florence: Oh, I'm so glad to hear that that was your experience. I'm just curious now also, was there anything that surprised you about the trial?  [00:16:35] Florence: You said there that you didn't really, like, have an understanding of cancer vaccines. You, you agreed to it straight away. Was there anything that maybe, like, you weren't expecting or surprised you?   [00:16:45] Ali: I think it surprised me that it was really quite easy.   [00:16:48] Florence: Yeah.   [00:16:49] Ali: Uh, I was delighted to have the team I had looking after me because they were fantastic. It all felt very simple.  [00:16:59] Ali: And how nice that was. You know, if I could've had that instead of all my previous treatments, um, it would've, it would've made everyone's life so much easier. And I guess, I don't know about the cost of drugs, but I guess the cost to the NHS would've been less because I wasn't in and out of hospital, I wasn't having to have all these extra things done, and all this extra support like dieticians and so on because I had to have my feed tube replaced.  [00:17:35] Ali: So all of that is impacts on the NHS, whereas this was very simple.   [00:17:40] Florence: I wanted to come to you now, Victoria, and ask you about the outcomes of this trial that Ali took part in or other trials like it, and whether we know yet what the broader implications of, of these advances might be.   [00:17:55] Victoria: So I think what we need to think about when we're thinking about developing these treatments and sort of evaluating the treatments at each stage is that it goes through a very clear pathway of progression, and Ali was involved in one of the, the earliest stages of that progression.  [00:18:09] Victoria: And it's, it's always amazing to me to hear your story, Ali, and to know that patients are willing to take part in the research and that's what allows us to develop these treatments. So the trial that Ali was part of has now gone on to develop into a, a larger scale study which will be evaluated again.  [00:18:27] Victoria: And that all starts to form the evidence for how these treatments can be shown to be effective, and also how they can show... Also, you know, Ali's already touched on there about the cost implications, so how we can show that that can be beneficial as well. And then we can start to think about how they can be taken up and become part of routine standard of care for patients like Ali, as she was describing.  [00:18:50] Victoria: And all of that evidence comes together, which then gets evaluated and then it, and then it moves forward through that progression. But it's-- we have very clear, um, you know, a, a route that each new, new treatment has to go through, um, to be able to, to become part of standard of care.   [00:19:07] Florence: And Victoria, you also play a key role in the Cancer Vaccine Launchpad.  [00:19:12] Florence: For any listeners who might not be familiar with the Cancer Vaccine Launchpad, could you maybe tell us a little bit more about it?   [00:19:18] Victoria: Absolutely. So in its simplest terms, the Cancer Vaccine Launchpad is designed to help find patients who might be eligible to take part in trials like the one that Ali was part of.  [00:19:30] Victoria: It's an incredible project. Cancer Vaccine Launchpad is quite long, so we tend to abbreviate it to the CVLP, which I'll do from now on, if that's okay. The CVLP to me really demonstrates the power of collaboration because it's brought together so many different teams that have been necessary to make sure that, that what we're trying to achieve, so finding as many patients as possible for these trials, is possible.  [00:19:52] Victoria: We deliver this project on behalf of NHS England. I know that Lennard was involved right from the start as well. The reason that we need the CVLP is because one of the biggest challenges in research of these new treatments is finding the patients who might be eligible. So one of the reasons for that is because when we are running the trials to test these new treatments, there's a lot of different infrastructure that's needed to support the delivery of those trials.  [00:20:19] Victoria: So you need special pharmacy services, special research nurses. All of that has to come together to be able to deliver trials of new treatments. And actually, that means that actually those studies can often only take part in a small number of hospitals. So historically, you only had the opportunity to take part in those trials if you lived near one of those hospitals, which is, you know, like Ali did.  [00:20:42] Victoria: So what the CVLP is, what, what it has done, it has created a formalised network which enables referrals to happen from ... we're opening 83 hospitals now across England. We've just expanded out to the devolved nations as well, which is a really exciting development, and it creates that, that network which allows patients who might live further away from a hospital delivering one of those vaccine or immunology trials to be able to be referred in to see if they might be eligible.  [00:21:09] Victoria: So essentially, it's a bit like creating a big funnel. So you're finding all of the potentially eligible people that could take part in that trial, and you're funnelling them into the trial site to find those patients who are eligible.   [00:21:22] Florence: And what impact do you hope that this could have for the NHS and also for, like, individual patients as well?  [00:21:29] Victoria: So we've seen such positive results from the CVLP so far. The first study that we worked with was for a colorectal cancer vaccine trial. Before the CVLP started working with this trial, only 17% of the eligible patient population in England had the opportunity to take part because they lived near one of those hospitals delivering the trial.  [00:21:52] Victoria: After the CVLP started working with it, we had increased that to over 60% of the eligible patient population. So you could really see how it has expanded out access, and that's just a fantastic opportunity to be able to bring, to bring patients. We also were able to show that the UK was screening, so looking for patients at three times the global average.  [00:22:14] Victoria: So we really were able to see how the CVLP is supporting and accelerating recruitment to those trials I think the key thing for me has been the patient enthusiasm that we have seen though. So when we open up to a new trial where, that the CVRP is working with, we are always inundated with people who contact us to find out how they can be part of this network because they want the opportunity to take part.  [00:22:40] Victoria: We know that some patients have travelled for two hours to a trial site to find out if they could be eligible because actually they want the opportunity. So the CVRP has really sort of enabled that patient choice, which is a fantastic thing to be able to do. But it also builds on what Lennard was talking about earlier, which is the UK is really good at this research and actually what the CVRP is then doing is showing how we can really support recruitment to these trials to accelerate these trials and that only brings more trials to the UK which again creates more opportunities for patients which is exactly what we're trying to do.  [00:23:14] Victoria: We're trying to create more and more opportunities for patients to take part in these studies if they want to.   [00:23:20] Florence: Yeah. That's really incredible. Thank you for sharing that with us. I wanted to ask you a question now, Ali, because I think when we were talking about trials and projects like this, as Victoria said, we often think about kind of the high level impact, but also it's an opportunity to create connections as well between patients and families and, and I know that you, you had a patient's family reach out to you about advice as to-- about whether they should take part in a trial. Is that right?   [00:23:47] Ali: Yeah. I think it was the wife of a guy up in Liverpool who had throat cancer, and, um, she must have done some really good research on the internet. I'd done various bits of publicity both for Southampton Uni and cancer research around the trial. So she obviously found me and then stalked me on Facebook , which was absolutely fine.  [00:24:13] Ali: I didn't have a problem. So her husband was down to go on the trial, which is the next stage that Victoria had spoken about, and she just wanted to know, would I recommend it, would-- what was it like, that kind of thing. So I said to her, "I would absolutely recommend it, of course," and told her what my experience was.  [00:24:35] Ali: I couldn't guarantee his would be the same, of course, because things might have moved on. But it was a really, it was a kind of a nice feeling that I could say to her, "Get him to have it done because it's got to be the best outcome." I think his stage was much further on than me. So yeah, it had to be the way as far as I could see for him. And as far as I know, he went on the trial. Which is great.   [00:25:05] Florence: How, how did it feel to kind of make that human connection, maybe not something you were expecting to come out of a trial?   [00:25:13] Ali: No, it was really, it was really nice. I am a bit of a, a fangirl for, for Lennard and Victoria and all the team at Southampton.  [00:25:22] Ali: If anybody asks me about vaccines and cancer vaccines, I'm like, "Oh, yes." And you-- So yeah, I'm, I'm a bit of an evangelist. So to, to have somebody real-   [00:25:33] Florence: Mm ...   [00:25:34] Ali: ask me about that was great feeling.   [00:25:37] Florence: I think that's a, a really great example of how research can have impact far beyond, uh, one individual. And I think another great example of this is also artificial intelligence or AI as a potentially transformative force in, in healthcare.  [00:25:54] Florence: Lennard, when we come onto this topic, I wanted to hand over to you because I know that you've recently received funding for a project exploring AI, and how it could support cancer vaccine development in particular. Could you tell us a bit more about this project?   [00:26:08] Lennard: Thanks very much, Florence. And I also want to add, I feel very proud about what Ali did just there, where she's able to bring through opportunity for other people, too, which is amazing.  [00:26:19] Lennard: The NHS is there to not just do the technology of today, but also be one of the best healthcare systems in the world to bring through new technologies. And it's just really exciting about people wanting to help the NHS, advocating for new technologies to be tested, and actually that's what Genomics England i there to do, make sure the NHS gets new technology in there so that patients will get new treatments.  [00:26:41] Lennard: I just wanna just reflect what Victoria noted In the NHS, in their Cancer Vaccine Launchpad, patients are getting in at three times the rate of other countries.   [00:26:51] Ali: Mm-hmm.   [00:26:52] Lennard: That's really special. And also she's increased coverage to, uh, did you say 60% of population? That's 42 million people have potential access to this.  [00:27:01] Lennard: So that is huge, and I think it's really a passion project for so many people out there, PICT trials units, the research nurses and doctors, and also patients who make this all happen. So it is quite impressive. It is very impressive. Oh, yes, and AI. I probably should cover that too. Just beyond what's special about the NHS and Genomics England.  [00:27:22] Lennard: Well, AI I think is changing everything. I went to a garden party, and actually everyone's talking about how they're using AI to make their lives simpler, make them do things that they've never been able to do before, get the information instantaneously there. And I think that there's technologies which come through every so often in our lifetimes, which changes how we think, how we communicate, and actually makes us better in many ways.  [00:27:47] Lennard: And so the great opportunity here is what happens if we take that third strength now? So we've already said we're really good at vaccine research in the UK. The UK invented vaccines. We also are world leaders at genomics. We did the 100,000 Genome Project. What happens if we use this new technology now?  [00:28:06] Lennard: And what's a problem that we can solve? Well, let's say we did a whole genome sequence on someone, which is what Genomics England does every day for the NHS. Well, that creates a lot of data. Um, I tried to do the calculations before we went online. It's about 100,000 photos. You know, when you take on your phone, that's a lot of data.  [00:28:25] Florence: Wow. Yeah.   [00:28:26] Lennard: And that's a miracle what's happening in the NHS and Genomic England, and we need to make a cancer vaccine out of that. And so you need to process that. So that's time-consuming. It could be automated. And so what AI could do now in future is that we could use the supercomputer we built in the UK.  [00:28:43] Lennard: In fact, we are doing this already. We've built supercomputers in the UK, and we're going well beyond other tools out there and designing cancer vaccines. And the AI scientists which can do that can do it at weekends, at nights, and help design the drugs. And so what it does is it heralds a future where every patient can contribute into a model that's created in the UK, stored safely in our supercomputers.  [00:29:07] Lennard: It can now be made into drugs, and the UK will start to make things again, which will hopefully change cancer care across the world. We can deliver that legacy whereby our three strongest strengths come together - vaccines, AI, and genomics. It then super powers the NHS and everything that Victoria's done in the Cancer Vaccine Launchpad, so many millions of people around the world can get access to trials.  [00:29:31] Lennard: And people like Ali can also help hold up the NHS even further. So people once again look back to us and say, "If you want to get things done, come to the NHS because it provides world-class care for patients." And so that's a big initiative now. Use AI to make better drugs, safer drugs, more effective, more precise in the UK. And it's only possible because of everything that we've built here with our funders, ARIA, MRC, Cancer Research UK, people raising, raising money through cake bake sales to make this happen.  [00:30:02] Lennard: So it's very exciting.   [00:30:04] Florence: Yeah. I think AI can be a topic that people often have very strong opinions about. When it comes to AI in, in your line of work, are there any misconceptions you think people might have, or are there any benefits to using it that maybe people might not be aware of?   [00:30:21] Lennard: Oh, that's a tricky question, isn't it? I think you're right. Any tool that comes through can be used for good things and, and things that people will question because maybe we don't want to cross those boundaries. And yet I think what we're doing here is really special because we want to - as long as your heart's in the right place - we want to give more people like Ali hope so that she knows that one day the drugs in the NHS will be much safer so you don't get all those side effects, much more effective, much more precise.  [00:30:52] Lennard: And on top of that, people like Victoria will be able to bring even more trials in the UK which will change lives and change practices around the world through an amazing working launchpad. So I think that's the right use of AI, make people's lives better. I think there are other uses of AI which I probably scratch my head and say, "Well, should we be doing that?"  [00:31:10] Lennard: And that's what I think it's really special that we do think about these and talk about these things here, and then bring the public with us because I know that people reach out, and Ali's been reached out in the past before, and I think we need to have this discussion here. Is AI right to develop cancer drugs using capabilities from Genomic England to go through the NHS Cancer Vaccine Launchpad?  [00:31:31] Lennard: I say cautiously, yes, and we should do more of this. And I think the most important thing is there's a lot of people starting to use AI for benefit, and you know my views, Ali, and I don't know if they're right. Um, I'll be a bit cautious, but I do want to ask you, Ali, is this the right use of AI? Should this be what we develop?  [00:31:50] Lennard: I don't know what you're going to say.   [00:31:52] Ali: For me, I think it is. I do think AI is a bit if you put rubbish in, you get rubbish out. But if you- If you ask the right questions, if you give it data analysis and experts like you have set up the protocol in the first place and it makes everything faster and reliable, then it's got to be the right thing.  [00:32:16] Ali: It gets used and abused for things, that isn't what AI should be doing, in my opinion. It should be used to do-- to help us, to supplement the work that we're doing, uh, and make it even faster than you're already making it.  [00:32:38] Florence: Well, we've covered so much today from how vaccines work to the role of genomics, NHS trials, and of course, what all of this could lead to. So before we wrap up, I have two final questions for each of you. What do you think is the most important thing for listeners to understand and take away from personalised cancer vaccines?  [00:33:01] Florence: And what are your hopes for the future? I think we'll start with you, Victoria, if that's all right.   [00:33:08] Victoria: Yeah, absolutely. It's been a great conversation. Uh, there's so much to think about. I think when I think about what I'd like listeners to take away, I think it's that cancer vaccines, and particularly personalised cancer vaccines, really support and represent this paradigm shift that we're seeing towards a much more personalised, uh, treatment pathway.  [00:33:27] Victoria: You know, like we've described, generating a cancer vaccine that has come from the patient's tumour, so the, the, the vaccine is, is designed to recognise mutations that are specific to that patient. It is such an incredible thing to be sort of witnessing and to see how that's developing through into sort of really changing patient care, and that's, you know, we've spoken about this so much, but that's been due to such incredible collaboration across scientific disciplines, across the NHS, pathologists.  [00:33:58] Victoria: Everyone has come together to make all of this possible, and that's, that's an amazing thing to be a part of. In terms of my hopes for the future, well, I would like the Cancer Vaccine Launchpad to be open in every hospital across the UK to really sort of underpin that acceleration and to provide that opportunity for patients.  [00:34:17] Victoria: You know, I'd just like to give a, a final shout-out to everybody who has been part of the Cancer Vaccine Launchpad from its very start, who's enabled this to happen and, you know, it's just been fantastic to see how this has, you know, supported patient choice for trials. And I guess if there's one tiny other thing, perhaps we could see how this, you know, this, what we've put together could be applied to other disease areas as well.  [00:34:39] Victoria: But yeah, that, that would be my hope for the future, is it's open everywhere one day.   [00:34:43] Florence: And Ali, I'll come over to you next.   [00:34:45] Ali: I think what I'd say to any patient that was asked to go on a trial is, is just go for it.  [00:35:02] Ali: And you know, Victoria, Lennard, all the rest of the team, you know, you are not doing jobs. You're leaving a legacy in my view. That's such an important thing. So yeah, if you're offered a trial, get on it. And my hope for the future is that everybody can have kinder, gentler treatments. The radiologists and chemo nurses I came across were lovely, lovely people.  [00:35:31] Ali: But yes, I'd like to see them out of work and doing other things within the NHS because they don't need to do that work anymore. That, that's my dream.   [00:35:40] Florence: Mm. And Lennard, any, any final thoughts?   [00:35:44] Lennard: Thanks, Ali. I mean, your words gave me goosebumps about the amazing stuff that the whole community's doing for cancer vaccines, AI and genomic research.  [00:35:51] Lennard: It's so powerful. Um, okay. What's the final thing? I think it's hope. Look, the country's in a new place now. You've got brilliant scientists running clinical trials, like the Cancer Vaccine Launchpad, which is reaching out to every single hospital. You've got patients who are building up the NHS again to deliver future care, and scientists using AI and genomics to make cancer vaccines.  [00:36:11] Lennard: That is a good reason to be hopeful. When lots of things are going in other places of the world, great things are happening in the UK.   [00:36:20] Florence: This has been such a brilliant conversation.  [00:36:25] Florence: A huge, huge thank you to our guests today, Dr. Victoria Goss, Professor Lennard Lee, and Ali Richards, for joining me in our brilliant discussion about cancer vaccines.   [00:36:50] Victoria: Thank you so much for having me.  [00:36:55] Ali: Thank you, as always. I've learnt a lot.   [00:37:00] Lennard: Thank you very much, Florence, too, from me.   [00:37:10] Florence: If listeners have enjoyed this episode and you'd like to hear more, please subscribe to Behind the Genes on your favourite podcast app.  [00:37:16] Florence: I've been your host, Florence Cornish, and Behind the Genes is produced by Deanna Barac, Sharon Jones, Sophie McLachlan, and Patrick Wallace at Bespoken Media. Thank you for listening.   

Send us Fan MailGambling harm can look like nothing more than “a flutter” right up until it has swallowed someone's work, relationships, confidence and mental health. I'm joined by Matt Smith, Director of External Affairs at Betknowmore UK, who speaks with rare honesty about his own recovery and why gambling addiction is so easy to hide even from yourself. We get into what harm actually means in day-to-day life: the shame that drives isolation, the cognitive dissonance that makes everything feel manageable when it is not, and the gaps that can appear when professionals do not yet have the right awareness or pathways. Matt also explains why gambling harm affects people from every background, and why “affected others” such as parents, partners and friends often carry serious distress in silence too. Matt breaks down how Betknowmore UK approaches gambling harms support as a public health issue, working with local authorities, NHS England and Public Health Scotland, and building community-based services that meet people where they already are. We talk prevention through accredited training, peer support through Peer Aid, women-only support via New Beginnings, and outreach like Goals that brings brief interventions into everyday community settings. We also explore the practical realities that sit underneath recovery, including debt, money taboo, and housing stability as a foundation for rebuilding life. If you find this conversation useful, please subscribe, share the episode with someone who might need it, and leave a review so more people can find practical, stigma-free gambling harm support and recovery stories.Contact Betknowmore UK: https://www.betknowmoreuk.org/LinkedIn: https://www.linkedin.com/company/betknowmore-uk/Instagram: https://www.instagram.com/betknowmoreuk/Welcome to Make Impact Podcast, where we dive deep into the stories, strategies, and solutions that drive real change. I'm Heidi Fisher and I work with organisations on a mission to tackle poverty, reduce health inequalities, and create lasting social impact. In each episode, I bring you inspiring conversations with change makers, social entrepreneurs, and thought leaders who are making a difference.  Thank you for joining us on this episode of the Make an Impact podcast. I hope you found today's conversation as inspiring and thought provoking as I did. If you enjoyed the episode, please subscribe, leave a review, and share it with others who want to create positive change. You can connect with me on LinkedIn and learn more about my work at Makeanimpactcic.co.uk.Until next time, let's keep making an impact in the world.Support the showHi, I'm Heidi Fisher, the host of the Make an Impact Podcast.  I'm an impact measurement expert, passionate about helping you make a bigger impact in the world by maximising the impact your services have. I can help you to measure, manage and communicate the impact you have better to funders, investors, commissioners and other stakeholders, and to systemise your data collection and analysis so that it frees up time and doesn't become an additional burden.  I love helping you to measure social and economic impacts, including Social Return on Investment or value for money assessments, as part of understanding the change you make to peoples' lives. You can get in touch via LinkedIn or the website makeanimpactcic.co.uk if you'd like to find out more about working with me.

This week we're focusing on how healthcare is using AI systems. The NHS is firmly set on a course of AI integration, with NHS England committing £10 billion of taxpayer funds to the cause over the next three years. The pressure to implement AI in our hospitals is intense. But, how can healthcare leaders know what makes for a good AI adoption strategy? Victor Montori and Jon Tilburt are physicians from the US' Mayo Clinic. They join us to lay out what they are calling the ‘five red flags' that any organisation needs to consider in its AI rollout.   The UK is already having this conversation. The National Commission into the Regulation of AI in Healthcare released its initial report in June of this year. Among its findings was a call for a ‘lifecycle-based approach' to regulation. To explain what this means, as well as how doctors can be equipped to ‘surveil' AI systems as conditions evolve, we're joined by the co-authors of a new BMJ editorial - Mark Ball from the University of Derby, and Elvira Perez Vallejos from the University of Nottingham.   And lastly, we talk about a research paper from last week that sparked off some concern. Researchers at Stanford University in California have used generative AI to design novel bacteriophage viruses. But, what have these scientists actually accomplished, and how can we put the right safeguards around the technology? Simon Clarke, associate professor in cellular microbiology at the University of Reading, explains the breakthrough and lays out its real implications.   References: We can, but should we? Red flags for hasty, low integrity AI integration into healthcare Regulating AI in healthcare: a moving target Developments in AI designed viruses demonstrate why such research must be done in the open

In a significant intervention this week the national safety watchdog has effectively called for a pause in the rollout of NHS England's “advice and guidance” policy after linking it to two patient deaths. On this episode we cover what prompted this review, why NHS England has been pushing the use of A&G for the last few years and what it's future could look like.

Contact us and share your opinionUnpacking the GP Patient Survey 2026: Methodology, Insights & Actionable TakeawaysIn this episode, we break down the newly released GP Patient Survey 2026 for England. We take a close look behind the headline numbers to examine the survey's methodology, analyze what the results actually mean for general practice, and share practical ways you can leverage these insights within your own practice.What We Cover- Beyond the Headlines: Addressing the "lazy" media narratives around GP performance versus the real data published by NHS England and Ipsos on July 9, 2026 (based on ~654,000 patient responses collected between January and April 2026).- Key Findings: Continuous improvements in patient satisfaction and digital access across the country.- Understanding the Methodology: How data is collected. Sampling techniques. Response rates and statistical validity- Putting the Results to Work for Your Practice:Navigating the official portal to look up your practiceBenchmarking against your Integrated Care Board (ICB) and neighbouring practices. Exporting data to Excel and generating presentation-ready infographic slides- Why Are Scores Improving?The hard work of primary care teamsThe impact of Primary Care Network (PCN) funding and expanded role flexibility (including GP and nurse support alongside physios, pharmacists, and personalized care teams)Resources & Links MentionedGP Patient Survey Official Portal:https://gp-patient.co.uk/GP Patient Survey 2026 Methodology & Technical Annex:https://gp-patient.co.uk/technical-annex-introduction-2026Media Article Discussed:https://www.mirror.co.uk/news/health/gp-doctor-general-practice-survey-37413432Join Dr Mike as he shares how to get started and fly using EMIS to make your life easier with this clinical systembit.ly/EMIScourse

On this episode we cover two interesting tech stories. Firstly, new estimates have suggested the federated data platform could have a benefit value of £1.7bn less than a figure given by NHS England a year ago.We talk more about this latest FDP story and what it could mean for the extension of the controversial Palantir contract next year.Also, the national safety watchdog announced last week it has launched in investigation into AI use within the NHS. We ask what prompted this and what it will explore.We also talk more about the news a North Devon maternity unit is closing due to a lack of doctors, and how trusts and the government are approaching this national problem.

This week Emma speaks to the new chair of the BMA England GP committee Dr Clare Bannon.Clare has been in the role for just over a month and, in this conversation, she sets out her priorities and her plans to reset the BMA's relationship with the government and NHS England.She discusses the committee's key demands, including an extra £40 to £50 per patient in core funding and meaningful GP contract reform - and the importance of establishing a roadmap to meet those aims.She also talks about the underemployment crisis facing sessional GPs, the controversy surrounding NHS England's list cleaning exercise, and concerns over single point of access referral pathways. And she shares her thoughts on neighbourhood health contracts and where the committee stands on further collective action - and a potential Plan B ballot.This episode is presented by GPonline editor Emma Bower. It was produced by Czarina Deen.Useful linksGP funding ‘has not kept pace' with exp[anding NHS roleGPs report patient harm as referral reforms kick inBMA sets out next step in collective action for AugustGPs denied billions as hospital funding grows 50% faster than primary careHalf of GPs say NHS general practice not financially viable ahead of 'Plan B' voteAggressive list cleaning to run over four-year cycle as reinvestment plans emerge Hosted on Acast. See acast.com/privacy for more information.

In this explainer episode, we've asked Dr Antonio D'Alessio, Medical Oncologist at Guys and St Thomas Foundation Trust, to explain cancer vaccines and how they work. You can also find a series of short videos explaining some of the common terms you might encounter about genomics on our YouTube channel. If you've got any questions, or have any other topics you'd like us to explain, let us know on podcast@genomicsengland.co.uk. You can download the transcript or read it below. Florence: What are cancer vaccines and how do they work? My name is Florence Cornish, and today I'm joined by Antonio D'Alessio, who is a medical oncologist ay Guy's and St Thomas' Foundation Trust and King's College. And he's going to be telling us much more about the topic. So Antonio, before we get into cancer vaccines, I wanted to first ask you about cancer. I know it's a pretty broad term, and it refers to the uncontrolled growth of cells in the body, but maybe it would be helpful for you to explain a little bit more about what cancer actually is, like what that term means, especially for listeners out there who might not have that scientific background. Antonio: Yeah, of course. And first of all, thanks for inviting me today. Well, that's a big question. The point is that we know that in our bodies there are billions of cells, and all of these cells, they divide, they do their job, and they know when to die on schedule. The point is that sometimes there are cells that ignore this instruction and just keep reproducing and growing, and this is when cancer grows. Our bodies have systems, which is the immune system, to recognize when this happens so that the immune system can recognize the cancer cells that are growing too much. They attack them and destroy them. But unfortunately, sometimes cancer is quite clever, they manage to escape from the immune system and starts growing without control, and that's when cancer starts. Florence: And so, what are the standard treatments that we use for cancer at the moment? Antonio: Well, broadly speaking, I would say that we have three types of cancer treatments. One, it's surgery, where we just cut the cancer out. Then we have radiotherapy, where we basically induce targeted damage to the cancer. And then we have a very broad umbrella term that is systemic therapy. Systemic therapies can be chemotherapy, can be targeted therapies, and that can be immunotherapy. In particular, immunotherapy is quite exciting because over the past 20 years, we have learned how to boost the immune system of patients, so that's the white blood cells, the immune system of patients that can recognize cancer cells and attack them. Sort of imagine that cancers hide behind an invisibility cloak, and immunotherapy helps unveil the cancer so that the immune system can recognize the cancer again and attack it. And vaccines and cancer vaccines are part of this family of immunotherapy drugs. Florence: Yeah so speaking about that, I think lots of listeners might have heard of the term cancer vaccine before, obviously, its the topic of this episode. And I think the term cancer vaccine sounds very interesting and promising, but also maybe a little bit intimidating as well. So maybe you could tell me more about what a cancer vaccine is kind of at the most basic level. Antonio: Well, cancer vaccine is a vaccine, and we have received so many vaccines in our lives that our body basically has learnt already how to process a vaccine. Imagine a vaccine as a wanted poster. So, we give the body the instructions to recognise something that shouldn't be there, and the immune system knows how to do it. So, the job of the immune system is to recognize strangers in our bodies - that can be microbes, bacteria, viruses, and also cancers. And sometimes with a vaccine, we sort of help the immune system to do its job a bit better. And with vaccines, we provide the instructions to recognize these strangers in our body and help the immune system to, to get rid of them. And in particular, for cancer vaccines, we have different types of cancer vaccines. There's a family of cancer vaccines that are called preventative, where we can try to give a vaccine even before the cancer develops to reduce the risk that the cancer develops. And, this is more early in the development. While we have, another family of cancer vaccine, which are mostly mRNA cancer vaccines that are called therapeutic. So these are cancer vaccines that are given to patients who already have cancer, maybe who had the surgery for their cancers, so that the aim of the cancer vaccine is to boost immune system and reduce the chances that the cancer comes back after surgery, or, help other types of immunotherapy work better together with vaccine against the cancer. Florence: So, I think for me at Genomics England, the mRNA cancer vaccines are probably most relevant to the work that we do here as an organization. Could you explain a little bit more about how those ones work specifically? Antonio: Yeah, that's an exciting field, right? The mRNA vaccine. So, let's split this into different words, mRNA and vaccine. We have just covered what vaccine means. We just have to think mRNA as just instructions. So we give the body of the patients the instruction to recognize the cancer. And the mRNA is basically the instruction for the immune system to recognize some of the proteins that are expressed on the cancer cells, so that's the white blood cells, the own white blood cells of the patients that can be more alert and identify the cancer cells if they are around. And in particular, imagine when we give the mRNA vaccine, it's like we are giving the picture of a suspect to the police, right? The police is the immune system of the patients, and the suspect is the cancer. And so, the immune system, so the police of our body, can go around the body, can go around the bloodstream, can go around the organs, and if they see the suspect, they are, they are already alerted, and they can tackle it, attack it, and destroy it before it develops into, into a cancer that can be seen on the scans.   Florence: And are these types or other types of cancer vaccines being used in the clinic at all in real medical settings already? Antonio: Well, I wouldn't say that we are using that in clinical practice, but probably in the future we will, and we are working hard to make sure that we will be able to use cancer vaccine for our patients. At this stage, we are using cancer vaccines as part of clinical trials, and these clinical trials cover different types of cancer types, different types of setting, together with other drugs or given alone after surgery, for instance. And the NHS England, Genomics England and NIHR, they launched this massive infrastructure that is called the Cancer Vaccine Launchpad. And it is aimed specifically to match the NHS cancer patients with personalized mRNA vaccine trials, so that once we have the results of those trials and we are ready to deploy it in clinical practice, then we already have the infrastructure to do that promptly, hopefully in the next future. Florence: Mm-hmm. Yeah, so do you see a future where cancer vaccines are used in routine care? Antonio: Well, we are working towards that. And I, and I do see a future where we're going to use that. I don't know when. Probably it will take still a few years. But the, for example, in the UK and in England in particular, we have a national cancer plan, and the national cancer plan for this year has identified cancer vaccine as a top priority for our health system. And this is because this is a technology that can be scalable, that can be widely deployed once it's demonstrated to be working. And at this stage, there are still some open questions, like which cancer types in which setting, which patients would benefit from it. But once we address these open questions in clinical trials, then I do believe that we'll be able to use that in the, in the future. Florence: I think we'll finish there. Thank you so much, Antonio, for coming on and for taking the time to talk to us. Antonio: Thank you Florence, and thank you for the invite. Florence: If listeners want to hear more explainer episodes like this, you can find them on our website at www.genomicsengland.co.uk or wherever you get your podcasts. Thank you for listening.

It was an absolute pleasure to record this conversation live at NHS Confed Expo 2026 with one of the NHS's most respected leaders.In this special live episode of Next GenCast, I sat down with Dame Caroline Clarke, Regional Director for NHS England in London, to explore the leadership journey that took her from NHS finance trainee to leading health services for almost 10 million Londoners.What followed was one of the most open and honest conversations I've had about leadership, resilience and staying true to your values.We talked about:Her unexpected route into NHS leadership and why she never had a grand career planLeading one of the UK's largest health systems through enormous changeImposter syndrome - and why it never completely disappearsLiving with multiple sclerosis while managing one of the NHS's biggest leadership rolesMindfulness, exercise and protecting your energy in demanding jobsRaising an adopted daughter alongside a national leadership career…and so much more.Whether you're an aspiring leader, an experienced clinician, or simply interested in what leadership really looks like behind the scenes at the highest levels of the NHS, I think you'll really enjoy this conversation.⏱️ What to expect03:30 Early influences and entering the NHS06:30 The finance perspective in healthcare09:30 From finance trainee to CEO13:30 Royal Free, technology and transformation15:30 Imposter syndrome and finding your voice20:30 Listening as a senior leader22:00 What it's really like at the top of the NHS26:00 Health, family and managing stress30:00 Mindfulness, teams and work-life balance33:00 Authenticity, inclusion and leadership36:00 Failure, mistakes and learning38:00 Career highlights and proudest moments39:30 Neighbourhood health and primary care41:30 Quick-fire leadership questions42:00 Advice for the next generation

This week, Ben is joined by Katie Collin, Partner at Ramsay Brown, to discuss NHS England's consultation on Single Neighbourhood Provider contracts and Multi-Neighbourhood Provider contracts. They explore what the proposed contracts could mean for GP practices, PCNs and federations, including the potential impact on funding, governance and locally commissioned services. Katie explains the different contract options, whether PCNs should consider incorporation, and the potential role of federations and collaboratives as MNPs. The discussion also looks at the opportunities and risks of shifting more services into primary care, and why strong governance, transparency and financial planning will be essential as neighbourhood working develops. With the consultation still underway, Katie shares her thoughts on what practices and PCNs should be considering now. Introduction (00:08) The NHS England consultation on neighbourhood provider contracts (00:30) Why the consultation is a positive step for general practice (00:51) Single Neighbourhood Provider contracts: what do they mean for GPs? (03:57) PCN DES vs a local variation: understanding the options (05:47) Could locally commissioned services move through PCNs? (08:39) The financial implications for GP practices (09:00) What the IIF taught us about collective funding (11:01) Why PCN governance could become more important than ever (13:40) Should PCNs consider incorporation? (15:29) The benefits of incorporation and stronger governance (15:57) What are Multi-Neighbourhood Providers (MNPs)? (18:16) Could MNPs create new opportunities for general practice? (20:18) The risks of following the funding into primary care (21:38) How can federations and collaboratives fit into the new model? (23:37) Why governance and transparency will be critical (25:06) What should PCNs and practices do next? (26:03) Visit Katie on Linkedin here, or email Katie directly here. Visit the Ramsay Brown website here. For all enquiries about the Ockham podcast, please contact Ben Gowland here.

“I had no idea this happened. Were we informed? I am very concerned about duty of candour here… Why weren't the victims informed immediately?”This was NHS England's response after learning of the records breach at University Hospitals of Liverpool Foundation Trust, revealed in emails obtained by HSJ this week.On this episode we talk more about what happened next, including the independent investigation ordered and Sir Jim Mackey's warning to trusts. Also this week we discuss a story that speaks to the ongoing concerns about culture within ambulances trusts.

Matthew Whitty is the former Director of Innovation, Research and Life Sciences at NHS England and now Director of Commercial Partnerships at MDClone, a global healthcare data platform. Combining senior NHS leadership with frontline experience in healthcare data and AI, he is an expert on NHS data strategy, safe AI adoption and how health systems can unlock the value of data while protecting patiWho actually owns your health data? Most people assume there's a single patient record sitting somewhere in the NHS. There isn't, and that gap sits at the heart of one of healthcare's most important and least understood debates.This week, Steve Roest is joined by Matthew Whitty, Director of Commercial Partnerships at MDClone and former Director of Innovation, Research and Life Sciences at NHS England. Drawing on a career that's spanned hospital pharmacy, commissioning, consultancy and national policy, Matt offers a rare view from the intersection of government, industry, academia and patient care.Together they unpack why the "privatisation" debate is really about trust and motivation, what the Federated Data Platform and the Palantir contract actually involve, and why de-identified data can still put patients at risk - including the recent UK Biobank breach. They also explore synthetic data, the case for sandbox environments that could make Britain the number one place to build healthtech, and why Matt believes there's far more reason for optimism about the NHS than the headlines suggest.In this episode:Why the NHS can't build everything itself, and what the private-sector "tension" is really aboutWho owns your health data, and why no single patient record existsThe Federated Data Platform and Palantir controversy, explainedHow de-identified data gets re-identified, and what happened with UK BiobankSynthetic data and the case for UK healthtech "sandboxes"Why the NHS may compare far better to other systems than people assume

A.M. Edition for July 30. Meta shares fall and Microsoft rallies after the hyperscalers sent very different signals on how they're monetizing their massive AI outlays. Plus, as some people are allowed to return to their homes in southwestern France, WSJ's Ed Ballard says a debate over aging water bombers and the country's readiness ahead of a summer of wildfires is picking up. And DoorDash secures a key certification from the FAA to use drones for deliveries. Luke Vargas hosts. Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The NHS became the world's first health system to commit to reaching net zero emissions in October 2020. But bold national commitments only become reality through the people doing the work at the point of care. In this Insight from Episode 104: Practicing Green Health, Emma Pascale Blakey, PhD, RN, Nurse Lead for Sustainability at NHS England, makes the case that nurses and midwives have a valuable perspective as researchers and scientists in this equation, and they are an invaluable resource when it comes to sustainability solutions. From drones delivering chemotherapy to the Isle of Wight, to health visitors cycling between family visits, to clinical procurement nurses influencing what equipment gets ordered, nurses are leading the way when it comes to sustainability.   To listen to this Insight clip's full episode, visit the SEE YOU NOW Podcast Episode 104: Practicing Green Health on APPLE, SPOTIFY, YOUTUBE, or your favorite streaming platform.   Learn more about See You Now. Visit the ANA Innovation website for additional resources. https://www.nursingworld.org/practice-policy/innovation   If you know a healthcare professional whose work reflects grit, innovation or extraordinary care—or if that story is your own—we encourage you to apply for the TIME Healthcare Champion of the Year, in partnership with Johnson & Johnson, a branded award.   Have questions or feedback for the SEE YOU NOW team? Future episode ideas? Contact us at hello@seeyounowpodcast.com. 

Send us Fan MailThis week on Just MS News, we lead with encouraging—but still early remyelination research.Scientists have identified an experimental small molecule that promoted oligodendrocyte development and remyelination in preclinical models. We explain how this candidate differs from PTD802, the remyelination therapy we recently covered as it prepared to enter human testing.We also look at:• Fampridine becoming routinely available through NHS England for eligible adults with MS-related walking difficulties• Evidence examining whether treatment escalation after clinically silent MRI lesions may reduce future relapse risk• New research exploring how anti-CD20 therapies may affect protective immune cells originating in the gut• A large U.S. analysis identifying racial, geographic and age-related disparities in MS-associated mortality• Two brothers continuing their remarkable marathon journey using an adaptive racing wheelchairARTICLES AND SOURCES1. A Novel Small Molecule Remyelination Therapy for Multiple Sclerosis   Source: npj Drug Discovery   https://www.nature.com/articles/s44386-026-00060-72. Thousands With MS to Get Fampridine on the NHS to Help Them Walk More Freely   Source: NHS England   https://www.england.nhs.uk/2026/07/thousands-ms-life-changing-drug-nhs-help-walk-more-freely/Clinical commissioning policy:https://www.england.nhs.uk/publication/clinical-commissioning-policy-prolonged-released-pr-fampridine-as-a-treatment-of-adults-with-multiple-sclerosis-and-associated-walking-impairment/3. Treatment Escalation After Clinically Silent MRI Lesions in Relapsing-Remitting Multiple Sclerosis   Source: Brain   https://academic.oup.com/brain/advance-article/doi/10.1093/brain/awag252/87413054. Anti-CD20 B-Cell Depletion Is Associated With Elevated Mucosal-Originating Circulating Immune Cells   Source: Science Translational Medicine   https://www.science.org/doi/10.1126/scitranslmed.aee15805. Racial and Ethnic Trends and Comorbidity Patterns in Multiple Sclerosis Mortality   Source: Neurology Open Access   https://www.neurology.org/doi/10.1212/WN9.00000000000001486. Man With MS Does Marathons With a Push From His Brother   Source: Deseret News   https://www.deseret.com/sports/2026/07/22/deseret-news-marathon-brian-danny-connolly-wheelchair-ms-people-with-disabilities/Just MS News provides accessible summaries of multiple sclerosis news and research. This episode is for informational purposes and should not replace guidance from your healthcare team.Visit Just Multiple Sclerosis:https://www.justmultiplesclerosis.comListen to the podcast:https://www.justmultiplesclerosis.com/podcast#MultipleSclerosis #MSNews #Remyelination #MSResearch #Fampridine #MultipleSclerosisResearchThe Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments.www.justmultiplesclerosis.com

This week we discuss why a £300,000 exit payment to a former ICB CEO has proved so controversial, and how NHS England has tried to justify the move.We also look at what the row reveals about the wider pressure ICBs are under, as they face deep cuts and continued uncertainty over their future role.This includes the questionable use of public money in wider ICB restructures, which are in many cases forced to pay for redundancies they may one day regret.And with devolution to mayoral strategic authorities, how do ICBs and ‘places' fit into the new world?

A rapid-fire segment highlighting positive developments in digital health. Janae and Megan share insights on recent innovations, successful implementations, and emerging trends that are driving progress in healthcare technology. Learn about cutting-edge solutions improving patient outcomes Discover how technology is enhancing healthcare accessibility Gain insight into successful digital health implementations Stay informed about positive industry trends shaping the future of care Janae Sharp, Founder, The Sharp Index Megan Antonelli, Chief Executive Officer, HealthIMPACT Live Subscribe to Digital Health Talks on Apple Podcasts, Spotify, YouTube, or wherever you listen. Learn more about HealthIMPACT Live events, virtual forums, and healthcare leader conversations at healthimpactlive.com. Interested in being a guest, sponsoring, or joining the HealthIMPACT community? Visit healthimpactlive.com/digital-health-talks. Subscribe to Digital Health Talks on Apple Podcasts, Spotify, YouTube, or wherever you listen.Learn more about HealthIMPACT Live events, virtual forums, and healthcare leader conversations at healthimpactlive.com.Interested in being a guest, sponsoring, or joining the HealthIMPACT community? Visit healthimpactlive.com/digital-health-talks.

Link to Pre Order: Tackling Gender Bias in The Healthcare System. What Patient stories Teach Us About Implementing Systemic Change: https://www.amazon.co.uk/Tackling-Gender-Bias-Healthcare-System/dp/1805018817This week we are Spilling The Tea with Nicky Denson-Elliott, a professional feminist, community builder, award-winning podcaster, and the woman asking a question that, once you hear it, you can't unhear it.We're talking about the word hysterectomy, a word one in five people don't even realise means the removal of the uterus. A word rooted in "hysteria," a diagnosis used for centuries to dismiss and pathologise women, only struck from medical record books in 1980.Nicky had a hysterectomy herself this year, and it crystallised something she'd already been thinking about as a feminist campaigner. She's now petitioning NHS England to retire the word "hysterectomy" in favour of uterectomy, clearer, more accurate, and free of centuries of baggage.Today we're talking medical misogyny, language, and why the words used for our bodies matter more than we think. We ask her about the petition and the moment that made her think "this word has to change"; how living through her own hysterectomy this year sharpened her view on the language; the real history connecting "hysterectomy" and "hysteria," and whether people actually know it; why a procedure that around one in five UK women will have has never had its language challenged before now; how she's finding getting the petition out there given the algorithm's treatment of women's health content (following our chat with the CensHERship Campaign last week); whether she's faced any opposition or the response has been entirely positive; and what NHS England and clinicians have said so far.We also cover the new terminology for PCOS, now PMOS, and what this name change could hopefully mean for people living with it. Stick around for some beautiful inspiration to carry you through the week.☕ SUBSCRIBE for honest chats on women's health, feminist issues, sisterhood & smashing the patriarchy, one cuppa at a time.

This week I spoke with Garland Nixon about the growing militarisation of western economies and societies: what is driving it and how is it impacting our lives? We talked about the huge propaganda drive against Russia, the constant talk about war spending and conscription and the multitude of ways in which the talk of existential threats and increased war spending are being normalised. We also talked about the threat that is posed to British imperialism by the anti-genocide movement, which, at its core, is an anti-imperialist movement. The need to suppress such activities explains the efforts the state put into to rig the trial of the Filton Six (who took direct action against the Zionist/Imperialist war machine in Britain) as well as the draconian targeting of health workers who oppose genocide in Britain. It is in this context that Dr Ranjeet Brar and the Right to Protest organisation have launched a judicial review to try to overturn NHS England's decision to adopt the IHRA 'definition of antisemitism' – a device which allows managers to discipline and even fire health workers who express support for Palestine and opposition to Israeli genocide. Original video: https://www.youtube.com/watch?v=vHY8aEswLW4 (originally streamed on 30 June 2026) ______________________________________________ Subscribe! Donate! Join us in building a bright future for humanity! http://www.thecommunists.org http://www.lalkar.org http://www.redyouth.org Telegram: https://t.me/thecommunists Twitter: / cpgbml Soundcloud: / proletarianradio Rumble: https://rumble.com/c/theCommunists Odysee: https://odysee.com/@proletariantv:2 Facebook: / cpgbml Online Shop: https://shop.thecommunists.org/ Education Program: Each one teach one! http://www.londonworker.org/education... Join the struggle! https://www.thecommunists.org/join/ Donate: https://www.thecommunists.org/donate/

Have you ever walked into a healthcare setting and felt like one part of your identity was being used to explain away everything else? This one is for you.Eva Echo (she/they) is a distinguished activist, writer, and TEDx speaker, focusing on transgender+ rights, intersectionality, and eating disorders. After hearing Eva speak at the Dump the Scales march, I basically ran after her to get her on the podcast, and I am so glad I did.Eva has spent years fighting for trans+ people in healthcare, including taking NHS England to the High Court over unlawful waiting times, and many other incredible projects. She also has her own lived experience of an eating disorder, autism, and ADHD, and this conversation weaves all of that together in a way I haven't heard anywhere else.In this episode, we explore:Eva's experience of restrictive eating and how it developed alongside her identity as a trans womanHow autism and ADHD intersect with her eating disorderThe moment a GP told Eva she couldn't have an eating disorder and it's lasting impactEva's experience of Trans broken arm syndromeWhat medical gatekeeping looks like across eating disorders, gender identity, and neurodivergence,Eva's legal challenge against NHS England and the landmark ruling that came from itWhy the NHS can feel like a conveyor belt instead of individualised careEva's path analogy in relation to eating disorder recoveryEva's message to anyone who has never felt truly seen or heardEva's message is simple, and I think it is everything: be your own kind of beautiful.Connect with Us:Subscribe to the Full of Beans PodcastFollow Full of Beans on InstagramCheck out our websiteListen on YouTubeConnect with Eva via Instagram (@evaech0)⚠️ Content Note: This episode contains discussions of eating disorders, medical gatekeeping, gender identity, neurodivergence, and experiences of suicidal ideation. Please take care of yourself while listening.Photo credit: Lunar Sea.

This week the team chat fake news, Farage calling a by-election and why the latest plan from NHS England makes sense. Who we are Simple Politics does things differently. We exist to help you have better conversations about the issues and the changes that matter. We do so by being clear, accurate and impartial. Also, light-hearted, engaging and occasionally (but not as often as we think) amusing. It's not just about understanding the facts and the topics themselves but also looking at why different people hold the opinions they do. Those with whom you disagree aren't monsters. Understanding and respect are at the core of everything we do. Our core offering will always be free. Unfortunately, giving things away for free isn't a great business model. We've never been business people. But. We do need to make this work. We do so through our amazing supporters, who keep us going by buying stuff in our shop and making monthly donations. This podcast has been Produced by Stripped Media If you want to know more about this podcast and others produced by Stripped Media, please visit www.Stripped.media or email Producers@Stripped.Media to find out! Learn more about your ad choices. Visit megaphone.fm/adchoices

Proletarian writers | 16 October 2026 This statement was issued on 18 June 2026 by Right to Protest Campaign. Please contact RtPcase@proton.me for media enquiries. Lawyers for the Right to Protest campaign have filed a judicial review claim, challenging the adoption by NHS England of the IHRA framework, which conflates anti-zionism with antisemitism and brands all criticism of Israel as ‘racism'. To claim that questioning the creation of Israel, or condemning the actions of its government, is inherently antisemitic is not only false but is a dangerous erosion of free expression. --------------------------------------------- Subscribe! Donate! Join us in building a bright future for humanity! www.thecommunists.org www.lalkar.org www.redyouth.org Telegram: t.me/thecommunists Twitter: twitter.com/cpgbml Soundcloud: @proletarianradio Rumble: rumble.com/c/theCommunists Odysee: odysee.com/@proletariantv:2 Facebook: www.facebook.com/cpgbml Online Shop: https://shop.thecommunists.org/ Education Program: https://thecommunists.org/education-programme/ Each one teach one! www.londonworker.org/education-programme/ Join the struggle www.thecommunists.org/join/ Donate: www.thecommunists.org/donate/

Maternity care and its shortcomings will be in the spotlight over the next fortnight, as the biggest maternity inquiry in the history of NHS England prepares to report its findings. The independent review by former midwife, Donna Ockenden, has looked into maternity services at Nottingham University Hospitals NHS Trust. Meanwhile new figures from the Royal College of Midwives show that more than nine out of 10 of those polled felt unsafe staffing levels are directly impacting the quality of care they provide for women and babies. Next week we'll also hear the recommendations of a national review by Baroness Amos. BBC's social affairs correspondent, Michael Buchanan, talks to presenter Nuala McGovern about what we know so far. Joanna Cherry was elected as an MP in 2015, part of the SNP landslide when they took 56 out of 59 Scottish seats, just a year after the referendum on Scottish independence resulted in a No vote. Her memoir, Keeping the Dream Alive, captures the disappointment and euphoria of that time. Joanna went on to lose her seat in 2024 and has become a vocal critic of the party, and of Nicola Sturgeon's leadership. She was also well-known for expressing gender-critical views and concerns at a time when the SNP was trying to deliver a gender self-ID law in Scotland. She joins presenter Nuala McGovern to talk about that "tumultuous decade" in Scottish politics.A new study from the Universities of Exeter and Bristol is looking into how heavy periods impact daily life. Led by Gemma Sharp, a Professor of Epidemiology at Exeter, researchers will collect real-time data from thousands of participants to help us understand the relationship between periods - particularly heavy periods - and our energy levels, sleep and mood. Did you know that mini golf has feminist roots? A playful and ‘playable' exhibition, The Art of Mini Golf, has just opened at the Battersea Arts Centre in London, channelling the inclusive, subversive spirit of the game's female founders. Nuala's joined by curator Grace Herbert and one of the featured artists, Delaine Le Bas, to hear more about mini golf's hidden history and the art it's inspired.Presented by: Nuala McGovern Produced by: Sarah Jane Griffiths

In this episode of the Transforming Primary Care podcast recorded in late March 2026, a panel of GPs and Practice Managers chaired by Mary Hudson, Deputy Director for Primary Care Transformation and Improvement at NHS England, discuss the difference digital tools have made to the patient journey. From online GP registration, to online consultations and appointment booking, all accessible via the NHS App, how have new modern ways of working made things quicker, easier and safer for patients and practice teams? For more information about Modern General Practice visit: https://www.england.nhs.uk/gp/national-general-practice-improvement-programme/modern-general-practi… A full transcript of this episode is available on our website - https://www.england.nhs.uk/long-read/online-gp-access-from-registration-to-routine/ Please get in touch if you have any questions regarding this episode - https://www.england.nhs.uk/long-read/online-gp-access-from-registration-to-routine/

The latest review of antisemitism in the health service serves to reinforce the action of the IHRA ‘definition' – ie, it seeks to stigmatise and victimise all those who speak out against zionist racism and genocide. https://www.youtube.com/watch?v=cAq8tg8Muok The video above contains information on a legal challenge that seeks to overturn NHS England's adoption of the IHRA definition of antisemitism. -------------------------------------------------------- Subscribe! Donate! Join us in building a bright future for humanity! www.thecommunists.org www.lalkar.org www.redyouth.org Telegram: t.me/thecommunists Twitter: twitter.com/cpgbml Soundcloud: @proletarianradio Rumble: rumble.com/c/theCommunists Odysee: odysee.com/@proletariantv:2 Facebook: www.facebook.com/cpgbml Online Shop: https://shop.thecommunists.org/ Education Program: https://thecommunists.org/education-programme/ Each one teach one! www.londonworker.org/education-programme/ Join the struggle www.thecommunists.org/join/ Donate: www.thecommunists.org/donate/

The country feels stuck. But can Britain prosper again? On the Prospect podcast this week, Prospect editor Philip Collins is joined by Ravi Gurumurthy to discuss this question. Ravi is CEO of Nesta, which is a research foundation and “innovation agency”. He is a lead non-executive of the Department for Energy and Net Zero and sits on the board of NHS England. Writing in a personal capacity, he also penned the cover story in this month's magazine (which you can read in full here.)Phil and Ravi discuss what changes the current government could make to re-energise the country, and debate everything from housing to data. Can the UK get the energy for a transformation? Hosted on Acast. See acast.com/privacy for more information.

The prime minister has accused Elon Musk of 'interfering' in UK politics, after he posted repeatedly on X about the police's treatment of Henry Nowak.NHS England says it will ban staff from wearing political badges as part of measures aimed at tacking antisemitism and other forms of racism. Britain's only serving female commando Lieutenant Lily-Mae Fisher has been named as one of the three members of the Royal Navy who died in a helicopter crash yesterday. She was on board the Merlin 4 aircraft alongside 42-year-old Lieutenant Commander Chris Gayson and 24-year-old Petty Officer Owen Green.Scotland's First Minister John Swinney has said his party may have claimed back tax on items purchased by its former chief executive Peter Murrell, who last week admitted embezzling more than 400 thousand pounds from the SNP.01:56 Henry Nowak treatment 06:50 NHS antisemitism measures 10:06 Helicopter pilots named 12:05 Lebanon ceasefire 15:04 SNP on Murrell's tax 17:46 World Cup water bottles 20:02 Teacher shortages 21:54 Hampshire rape sentencing 24:30 Strikes in Crimea 27:59 Bob Harris tribute(Image: Reuters)

It has been a tumultuous time in UK health politics. UK Health Minister ,Wes Streeting, has freshly resigned. What does this mean for his newly introduced NHS Modernization Bill as it heads through Parliament? Together with Hugh Alderwick, Director of Policy and Research at the Health Foundation, we unpack the bill's sweeping centralization of power, the abolition of NHS England, and the contentious role for US tech firm Palantir in the new NHS. And, we explore a major milestone for women's healthcare. A condition affecting an estimated 170 million women globally has officially been renamed from Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). Rachel Morman, Chair of the PMOS charity Verity, joins us to explain why dropping "cysts" from the name is a vital step toward recognizing this as a complex, multi-system condition, and how this co-designed change will fundamentally reshape diagnosis, treatment, and future research. Further reading: Health Bill brings NHS management back into government PMOS: What's in a name? Everything PCOS name change to PMOS must be managed to avoid confusing patients, says expert

Tom Bartlett spent 22 years inside the NHS. For three and a half years, he led the 150-person engineering team at NHS England that built the £330M Federated Data Platform with Palantir.He a month ago and he's the only insider speaking publicly about what the platform actually does, what it costs, and whether the NHS has any credible alternative.We cover the architecture, the cost, the CLOUD Act, the BMJ exposé, the conflicts of interest at Chelsea & Westminster, and whether ministers should trigger the break clause.

In this episode, we celebrate 10 years of the Participant Panel and explore how genomic research is being guided by patient and participant voices.  Made up of people who have consented for their genome, or the genome of their loved one, to be included in the National Genomics Research Library, the Panel plays a vital role in shaping how research is designed, how data is used, and how genomics is communicated. From influencing policy discussions to to advising the Genomics England board, their work helps ensure lived experience is embedded from the very beginning.  Over the past decade, the Panel has driven meaningful change. From advocating for greater transparency and accessibility, to challenging how the genomics community talks about genetic conditions. But beyond the impact, this episode focuses on the people behind the work: their motivations, experiences, and the realities of representing a wider community.  Our host, Sharon Jones is joined by:  Kirsty Irvine – Chair of the Participant Panel and member of the NHS Genomic Medical Service People and Communities Forum  Lisa Beaton - member of the Participant Panel, panel member for the North East and Yorkshire GMSA and research and development for Harrogate Hospital Foundation Trust  Frances Allan – member of the Participant Panel and member of the following:  CRUK Women+s Cancers PPIE at Cambridge MHRA Yellowcard Biobank Northumberland NHS health forum Ovacome Healthforum IMPRESS cancer diagnostic tool study participant  You can find out more about the Participant Panel in our recent Genomics 101 episode which Lisa featured in, titled ‘What is the Participant Panel?', and you can read about their timeline of achievements over the last 10 years.   “One of the things as participants that we're always really keen to get across, particularly to the scientists, is that behind every piece of data is a face and a name”   You can download the transcript, or read it below. Sharon Jones: This time on Behind the Genes, we'll be celebrating the 10th anniversary of the Participant Panel, and we'll discuss how genomic research is being guided by patient and participant voices. The panel is made up of participants whose data is held in the National Genomic Research Library. They help us to put lived experience at the heart of our work. My name is Sharon Jones, and in this podcast we cover everything from cutting-edge research to real-life stories in genomic healthcare. Joining me this time are Kirsty Irvine, chair of the Participant Panel, and Frances Allan and Lisa Beaton, who are also both members. Collectively, they wear many hats for a range of organisations, which are listed in the episode description. As you'll hear, this one is all about people power. So back in 2016, the Participant Panel was in its infancy, with 12 founding members bringing lived experience of rare conditions. The idea was straightforward but radical: that the people whose genomes were being sequenced should have a real say in how the work was done. Over the decade since, the Panel has shaped some significant changes, from pushing for a service that let participants track their own samples, to publishing a language guide that changed how the genomics community talks about genetic conditions and disability. They've navigated the pandemic, welcomed new members and, in 2025, launched their first formal strategy. This year they mark their 10th anniversary, and today we're hearing from some of the people who've been part of that story. So welcome Kirsty, Frances and Lisa. So what was your reason for joining the Participant Panel? And I will ask Frances that. Frances Allan: Hi Sharon. I joined the Panel back in 2023 following a cancer diagnosis, and as part of that investigation I was fortunate enough to have a whole genome sequence performed. And they also asked would I be interested in taking part in a panel who look after this information, and I ticked the box and then thought no more of it. And then a month or so later I heard from the then Chair, Jillian, um, and had a chat about genomics and joined the Panel, and it was a very good decision that I made. Sharon Jones: Did you have any kind of expectations? What were your early thoughts when you kind of accepted? Frances Allan: Not many thoughts. So I was in the middle of my chemotherapy treatment, but one of the things that really stood out: when I signed the consent form, I said, well, of course I would do that. And the clinician consenting me, said, actually, not everybody does. And I thought, well, why would they not want to do that? So I was really interested in finding out about that. I had no idea how influential the Panel was, and that was great to discover as I became part of it. But seeing the breadth of the research and the knowledge already gained, compared to my rudimentary A-level Biology from many, many years ago, gave me incredible hope, um, and really helped me through a very difficult, difficult time. Sharon Jones: Yeah, that's, that's amazing. It's amazing that you could kind of think in that way whilst you were actually going through the treatment itself. I mean, how did you split yourself in that way? Frances Allan: I think it gave me a sense of, of purpose. So at the time, I'd, I'd stopped working to have my treatment and I was a, a vet previously, so I was used to thinking about medical things and problem solving, and it, it filled a, a void in my life. I had no idea I'd be able to contribute to it. I thought, well, I'd learn something from it. But, you know, the, the Panel is managed very well. Kirsty's a fantastic Chair. Everybody gets an opportunity to speak, and the attendance can be in person. And I've done most of them in person. When I was poorly I attended an online meeting, but even that is managed so well that you get a chance to speak up. If you're not feeling well enough, then you can, you can add it to the chat or email. So it's very, very inclusive and a very supportive environment, as well. Sharon Jones: Yeah, it sounds like a, a very safe space to be in. And Lisa, what was your reason for joining the Participant Panel? Lisa Beaton: I think it was sort of one of those, bit of a light bulb moment for me thinking, yeah, I could do that. I'm not quite sure why I felt I was qualified to do that, but my reasoning is slightly different than Frances. So I joined the 100,000 Genomes Project back in 2015 in respect of one of my children who has an undiagnosed, thought to be neuromuscular, syndrome. Um, so myself, my husband and our daughter recruited for genetic sampling, and over the years I've sort of taken a keen interest in all things genetic and genomic related, followed on kind of various social media platform. And I think if memory serves, I saw an announcement or an advert stating, do you want to be part of the Participant Panel, clicked on the link and thought, this is something that really resonates with me. I've served with different hats on different kind of participant groups and speaking events, and it's something I feel really, it's an overused phrase, but I do feel really passionate and strong about it because, you know, we are the people who are the front and centre of this, because it's our genetic information. So I applied, did a bit of a kind of resume of myself, um, then had huge imposter syndrome and thought, oh, that'll be the last I'll ever hear of that. And uh, actually had a really lovely interview with some of the then, uh, members of the Panel and must have said a few of the right things, 'cause here I am, three years down the line. Sharon Jones: That's amazing. Has it lived up to your expectation? How has it, how has it helped you get through what sounds like a really challenging time? Lisa Beaton: It's, it probably sounds wrong to say I, I didn't really have an expectation, but I joined it really just wanting to kind of know more and see if I could find out more details, more information, kind of more genomic discovery, and hope that I could give something back, if that doesn't sound too cringey. I think one of the things I'm always really keen to say is that you don't need to be a geneticist. You don't need to be a scientist. You don't need to kind of have lots of scientific information. And I will confess that the very first meeting I went to, I did come away thinking, I think I probably only understood about one word in three. But three years down line as I say, I'm still here, and it's been good to challenge myself and to explore kind of things that I don't know information about, but also I found that there are areas that I can definitely bring lived experience to and, and hopefully a voice for people like myself and my family. Sharon Jones: Yeah. That's so important. It sounds like you've become a bit of an expert by, uh, experience there. Has your vocabulary improved in the last three years? Do you know more words now? Lisa Beaton: Yes. Uh, I've, I have to remind myself not to use an acronym. It's one of my pet peeves. You know, when you're, you're in a, a meeting and terminology or, or vernacular, that is not necessarily something that people would use day-to-day, and I think lots of you know, you don't, don't have to be genomics or genetics to, um, using acronyms for things. It's something we all need to remind ourselves that just because you know that expression, somebody else doesn't. So it's really important to kind of keep that at a, a lay explanation so that everybody understands it. Um, I think particularly with quite heavy subject matter such as genomics and genetics, there can be a tendency otherwise for people to feel that it's not for them. And of course it is, because it's about our own personal data. Sharon Jones: Yeah, absolutely. And, um, and coming to you, Kirsty, what were your kind of motivations for, for joining the Participant Panel? Kirsty Irvine: Well, it's been quite a long journey for me to find myself on the Participant Panel, so I and my family, we were all consented into the a 100,000 Genomes Project back in 2015. But from that point, I then spent nearly 10 years chairing committees at NHS Digital and then NHS England, focusing on health data access. And I remember talking about the 100,000 Genomes Project at my interviews for those roles. I then went down a different path. And in those roles I was very much wearing my solicitor's hat. So I was thinking about governance and risk and were we complying with the precise wording of the legislation. And then when the chair role came available, I had a number of people sort of forward it to me saying, I think this would suit you. I think this would suit you. And at that stage, I was aware of the Panel because I'd met the fantastic former chair, Jillian. Um, so I'd seen Jillian at various conferences and meetings and things, so I was well aware of what the Panel did. I was well aware of the Panel's standing. It was probably the only participant panel that I was aware of in my work with NHS Digital, NHS England. And then I realised, you know, I wanted to be closer to the people behind the data and I wanted to do something more active. I wanted to bring a bit more of myself. Because when you're chairing a very formal committee, at NHS England, you, you can't talk about the time that you resuscitated your child at home, you know? And on the Panel, you know, my very first meeting, I, I met someone, someone whose child had, you know, been fed with an NG tube for a number of months. You know, I met someone else who had resuscitated their child, you know, and all of a sudden I could bring more of myself to my colleagues and, and find a real community. So for me, joining the participant panel was a way of shifting the perspective, but to also bring that experience with me because I, the roles at NHS England, you know, from a governance perspective, I couldn't continue chairing those, you know, board subcommittees forever. But I didn't want that knowledge to just sort of disappear. So for me, I'm really delighted that I've, what I hope, what I hope is a good fit. I feel it's a good fit. So that, that's been my journey to the Panel. Sharon Jones: Yeah, that's, that's so interesting. And I guess having that space to kind of be yourself, and having understanding because of your lived experience, brings a lot of value to the role that you're doing now in a way that kind of is different when you're in your previous roles of NHS Digital, because you had to be a bit more, kind of stand back from it and, yeah. That's so interesting. So, what has it been like being part of these groups? You know, the ones that you kind of, you're involved in a lot of things, and we'll list them in the, in the web description. And how has it kind of affected your life, essentially, because it's not the kind of average thing that people are involved in. Frances Allan: So it's been an incredible, I think as Lisa alluded to, incredible learning curve. We've learnt so much. But the team at Genomics England are endlessly patient and very skilful at passing that information on. And we have access to the leading researchers, the clinicians that are involved in genomics. And they're happy to take any question. And the questions, however silly, there's no silly question. They're happy to answer that. And so we learn every time we attend a meeting, we have quarterly meetings and that can be in person or online. Um, but we also have regular lunch-and-learns. So if there's somebody we want to speak to or find more about their specialist area, they'll come and have a, a chat with us. And then we have half of it, them chatting to us and half us, us. Us asking them questions and, and challenging them. Um, so it's very, very informative and then learning from each other. And as Kirsty was saying, you know, this is a, a group of people who've, who've dealt with an awful lot of unique situations and they're happy to, to share that and pass on the information. It's a, it's a great place of learning. Sharon Jones: Lisa, would you agree with that? How it been for you? Lisa Beaton: Yeah, I would definitely echo everything that Frances has actually said there, and I think it's a very humbling experience, as well. Ostensibly, we are a, a collection of individuals who have all been brought together, um, purely because of, uh, our genomic interests. And whether that's for our families, you know, as, as parents, as in my case, or in somebody like Frances' case, who's obviously a participant in her, in her own right. And although there are kind of many differences in our stories, there's also a lot of similarities. But I think what's really interesting, very precious, is that the staff at Genomics England, obviously they range from, you know, there, there's so many different kind of areas from the, the comms, the scientists, etc., but everybody is really interested. They want to know your story, who you are, why you are there. There's a real kind of inclusion focus on that. And one of the things as participants that we're always really keen to get across, particularly to the scientists, is that, you know, behind every piece of data is a face and a name. And I think they really make that felt when they're chatting to us. You know, we go in and, and there, there's people who are there from governance sides for how the data is accessed by other parties. There's people there who are the science technicians, etc. There's people who are dealing with the administrative side of things, but every single person that I've encountered wants to know more about you, what you are there for. And that is, is very, very precious. And as Kirsty also alluded to, a lot of us have been through some really quite traumatic experiences. It, it's not my place to speak of others' journeys, but you know, there, there are, uh, bereaved parents and family members among us. And so we are sharing very precious raw material, emotions, experiences, and that is very powerful, as well. And I, I think the Genomics England staff never forget that. They seem to bear that at the forefront of their, their communications with us, always. Um, and certainly Kirsty and Adam and previous chairs, uh, of the panel, that inclusivity was entirely throughout every dealing we had with them. Sharon Jones: It's very humanising and I think that it's humbling for us who work here that that's always at the forefront of our mind, that this is why we kind of get up and go to work every day, because of that human element. And it's not just a data point. There is a whole family, a story, a history, and that's, that's so important to us in the work that we do. Kirsty, did you want to add your point on this as well? Kirsty Irvine: I've probably got two points I wanted to raise. One was just to draw out what Lisa was saying, is that it can be complex being a Panel member, because the story you're bringing often isn't just your own. In my family, we've got a real, we've got a whole range of genetic differences and conditions that, you know, across the extended family. And so when I speak, I'm often drawing on experiences that aren't solely mine to share, and, you know. So I think that's something that for some on the Panel, we're sort of, we're, we're being quite careful to think about what we're saying, and if we're speaking in the public domain, we might be talking about it in more general terms. So that's, you know, but there's not a single right way, and there's room on the Panel, everyone, for the people who can and, and as Lisa talked about, you know, the, the most acute situation is where someone's bereaved, you know. And it's, so everyone's got different, you know, different experiences. But that, that, again, coming back to the positive side of things, one of the biggest things to me about being on the Panel, what it means to me, is being part of a wider community. I mean, one of the other things that, Sharon, I don't know if I can sort of segue onto this about, you know, the opportunities that have arisen? Sharon Jones: Yeah, absolutely. I'd love to hear more about that. Kirsty Irvine: So one thing that really stands out for me was the opportunity to speak directly with, um, Associate Health Minister Ahmed about, and his policy team. So we went to the department, Adam and I went to the Department of Health, and it was about the use of GP data in consented research cohorts. So getting the GP data into the National Genomic Research Library. So even though there's consent, up until now, that GP data, that tranche of really rich data, hasn't, hasn't gone into the NGRL. So I'll use that abbreviation now that I've used it in full. And so what was really unique for me was that I'd seen it from multiple angles because I'm participant in the 100,000 Genomes Project, so I'm a cohort member. I then worked on the consent review for NHS England. I then sat on a, the consent review assessment committee with, you know, a multiparty group. And then, because I was on the panel, I got to see things full circle. I was then invited to, to go and meet with, um, Minister Ahmed and, and advocate for the use of this GP data. And that really matters because something, you know, there's such important information sitting in that GP data and it wasn't a given, it was not a given that the government was going to the direction that allowed that data to go into the NGRL. And so we were able to talk about how we really wanted that data to be used. And now, going forward, you know, something as simple as BMI or for example, if a, if an individual's coded for a neuro, neurodevelopmental condition like autism, sometimes that data actually only sits in the GP health record. It's in primary care only, so it's not necessarily in the hospital records or other records. And so this is really, really valuable data for, for researchers. And so that was something that was a really special experience, just being able to see that come full circle. And I felt like it's a really tangible example of how the participant voices really helped strengthen that conversation, you know, with the DH policy team, you know, and the government ministers. Sharon Jones: Yeah, I mean that's, that's really powerful and it, it just sort of shows how these opportunities can arise from being involved in a participant panel in a way that you wouldn't have necessarily had that power if you hadn't been involved. And you know, obviously you are wearing lots of different hats in that, in that position, Kirsty. And um, it just sort of shows what can be done when you're, unfortunately, you know, you're in this group for a reason and it's not necessarily the, the most cheeriest reasons, but it, you still leverage that opportunity to create something positive, you know, with it. Frances Allan: So we've given all sorts of opportunities and we seek to get involved with as many things as we can to speak and have our voice heard. Um, and one of the things I did last year was, um, do a short presentation to open a stage at the Genomics England Research Summit, which was quite a challenge for me, but I felt very exhilarated having done it. And then a couple of people came up afterwards and just said, oh, thank you for sharing your story. And a researcher who was slightly older than I, so very experienced, been in his field a long, long time, and he said his clinical years were long behind him, and now he researches within a lab. And actually for someone to say, you know, thank you for, for looking, thank you for finding, had a very profound experience on him. And he knew there was a clinical benefit; his research was very clinically led. But he said he hadn't thought about the recipients of those findings. And I pointed out every time you have that chat with somebody, come to an event like that, have a network, spend a bit longer in the lab, look for something that you might not find, even if it's a negative finding, there will be somebody eventually that benefits from that. And I've been a direct recipient of other people putting forward their whole genome sequence, and then a common change was noted in people with the type of cancer that I have, and that then qualified me for a treatment that otherwise I wouldn't have been eligible for, and I wouldn't have been, I wouldn't have been here now. So it's a very, you know, profound thanks to all the people that are involved from everybody within Genomics England, all the researchers, all the other patients that speak up. We each have a contribution to make. Sharon Jones: Yeah, that's amazing. That must have been quite a poignant experience when you, you met him at the, um, Summit, of just kind of the other side of the, the world that you don't often see. And they obviously don't see our side of the world, and it's kind of interesting to join those dots and kind of come full circle. So moving on. In terms of like, collectively, there's a lot of impact that you have and there's a noticeable shift in organisations where people with lived experience are playing, you know, a much bigger role in decision making. Can you help our listeners understand how people are getting involved in governance and shaping research? Lisa Beaton: From my perspective, it comes back to that word "embedding". I think historically, perhaps there's been an, an almost about-face. Um, it's kind of come at it very backwards, that that embedding has almost happened as an afterthought, which is sort of a bit of a misnomer way of explaining it. When you're talking about embedding, obviously it should be the foundation. Historically, at least both from the parent, parental perspective, I've seen that with clinicians, for example, that historically I've been made perhaps to feel a bit of a thorn in someone's side, that even though we're there for an appointment about our young person, when I'm asking questions that they don't necessarily want to answer, you know, I'm almost the, the add-on rather than the reason that we're there. And I think there has been a paradigm shift in everybody's approach to that. So thinking much more about, you know, the, the what's, the wherefores, the whys. How do we ensure that right from the get go, that patient or participant voice is heard, and it shapes the question. And one of our other Panel members frequently uses the phrase, "nothing about us without us", because that is front and centre of why, you know, genomics exists in the first place, really. Without that data, the conversation ceased to exist. It, it's so vitally important, not just for us as an individual, not just for our family members, but for the greater good, if that doesn't sound too grandiose. Sharon Jones: No, not at all. And, and, and Frances? Frances Allan: I think having raised that value of patient advocacy: what we have to say. So it started off, people felt that they should have some, so they included it, but actually once they started to include it, they thought, this does contribute to our study. And starting at the very beginning of the research project, so what is reasonable to ask participants and patients to do? Is it something that there is benefit from? And trying to see that end goal right at the beginning. And we might help shape a research study that actually goes in a beneficial direction, rather than the researchers starting alone, and then actually getting into the study, and the procedure is, is too painful to endure, there's no clinical benefit, it's not something that can be translated into clinical practice, and it gets abandoned. So start us right at the very beginning, and our perspectives may not be what, what researchers or clinicians think. Uh, with that lived experience, however empathetic you are, the lived experience is a very unique lens and position to look from. Sharon Jones: Yeah, it absolutely is. So, given that you are part of a small group and you know, you're representing a much wider community, essentially, like, what are the considerations that you, you have to bear in mind? Lisa Beaton: I think we can only speak, obviously, to our own individual experience and we are very aware that, you know, diversity, ethnicity, inclusion is something that is a much bigger conversation and certainly something that we want to broaden in, in the panel itself. And I know there's kind of lots of work and thought going into how that can widen those perhaps more diverse communities that historically... It's not that, there's, there's been a terminology that, you know, they're difficult to access, but actually the question is wrong there. The statement is wrong. It's not that they're difficult to access, it's just that we've been asking that incorrectly. And we need to ensure that they are, uh, empowered to bring their stories forward and find ways to push forward for their inclusion. We need to ensure that everybody's voices are heard, otherwise the data set is wrong from the off. So I think that's something that we're all very minded when we speak about, and definitely want to, to diversify the pools of data that come in. That, that has huge resonance for, you know, shaping genomic and genetic policies moving forward, for sure. Sharon Jones: Yeah, definitely. Frances, sort of broadening out that question. Does it feel like a lot of pressure and a lot of responsibility, kind of representing, you know, in this kind of small group where you are almost speaking on behalf of, you know, a lot of people? Frances Allan: I think it mainly feels like a, a privilege, Sharon, to be in that position, to have a say. And back to my, one of my motivators for joining is why would people not choose to do this? And actually understanding why that is. And is it the, you know, the lack of knowledge of genomics? And there is a lot of, of fear about what can be discovered. But understanding the immense benefits from that so people don't miss out on those opportunities. Our genomes contain the, the blueprint to us, but also how we would respond in certain situations, and you want everybody to be using those leverage points. You know, cancer's a really difficult disease to manage, and anything you can do to make it slightly easier, slightly more comfortable, slightly more successful, we want to do that. So every time we speak out and we advocate for the benefits of genomics, we might gain one more person who's going to feel that a successful outcome. Sharon Jones: Yeah, and who knows what, what that can mean for their family and, and sort of further down the line. So have you got any advice for, or encouragement, or any tips for, you know, potential participants who are thinking of getting involved in, in groups? You know, it doesn't necessarily mean the Participant Panel, but just generally, sort of groups related to their conditions or their family's conditions. Frances Allan: Yeah, I think the value of the one's personal experience: don't underestimate that. Everybody has an individual journey and they can comment and reflect on that. And anybody interested in, in joining our panel, you can include in the, the copy or description, ways they're getting in touch with us and speak to us about what that, what that involves. And uh, Lisa said at the, the beginning, you come and it's a huge learning curve, but there are people to support you and guide you through that way. And the learning is, is just fascinating. And there's a position for everybody and everybody's point of view to be heard, and you will be heard. Sharon Jones: Thank you. Lisa? Lisa Beaton: Yeah, I think I might steal a phrase or two actually from some, uh, well-known brands. But, um, one would be "just do it" and the other would be "feel the fear and do it anyway" because, you know, you are amongst friends, first and foremost. We all, we do tailor our experiences, and clearly we self-censor at times because that's necessary to protect the privacy and dignity of not necessarily ourselves, but as we've already alluded to in our chats, but you know, our family members, the wider people that you are aware will be hearing this. And you don't necessarily want certain medical information about your family members out there, because it's not your information to share. But in terms of joining the panel and, you know, having a voice, giving more voices, giving more diverse data, we, we need as many people as possible to come. We need more voices. We need to get our genetic, genomic information out there, uh, in front of the researchers and, and all involved with Genomics England, um, and other patient advocacy groups, as well, because that will only benefit the greater public. Sharon Jones: Thank you. And Kirsty? Kirsty Irvine: I'm just thinking about sort of general tips building on what Lisa and Frances have said. You don't need to be a seasoned public speaker. I think that's something, absolutely not. We've got some fantastic speakers in the group. Um, but then we've got people in the group who've got, who have got different skills, so don't think that you need to be ready to give a TED Talk at the first meeting, be that the Participant Panel or whatever group you might be motivated to join. We, we just need good listeners. I've chaired meetings in the past where people, uh, wanted to contribute via the chat function, and that worked absolutely fine. They would put their incredibly insightful, erudite comments in the chat, and then I would relay them to the group, and that was how we got that person's input, because we realised that they weren't necessarily going to speak up in the forum. So whatever your communication style, we can accommodate it at the Participant Panel and we would be delighted to hear from you. Sharon Jones: That's great. Thank you. Um, final question. So what do you hope the next 10 years of participant involvement will look like? Kirsty Irvine: I think if I could use a little catchphrase, which I'm sure is not mine, but I would like to see us fully integrated as partners, not participants. I'll put that out there. I mean, Sharon, I wonder if I could sort of also open things up to how are things going to look in another 10 years, because there's been some statistics that have really struck me, uh, at presentations that, that we've heard. One of them being that in the next, you know, within 10 years, around about half the data in the National Genomics Research Library will be from, I don't know if this is the best name for it, the general population. So that's people who aren't necessarily seeking an answer, or have a diagnosis or a condition. These are people who have donated their genomic data through being part of, you know, research projects. And, as a panel, so Genomics England's evolving and the panel will be evolving. And in 10 years time, the panel will need to be, I believe, true to the original route. So, 100,000 Genomes Project. Uh, the people who've had their whole genome sequencing through cancer diagnoses. You know, there's a significant COVID cohort, but also people of the gen, general population. So how do we advocate for and look after everyone in that broad group of people. So I think that, that's both a challenge, that's a challenge for us, but it's also really exciting to think how we can meet that challenge. Sharon Jones: Yeah, definitely one, definitely an opportunity and a challenge, and one that will take a lot of thinking in the next few years. Frances? Frances Allan: Yeah, thanks Sharon. I think looking forward to that, that 10-year period is how genomics just becomes a normal part of everybody's healthcare, so we all fully understand the benefits of it. People are willing to participate in it and then using lots of different types of data to go into the National Genomics Research Library. So at the moment, it's mainly genomics material, but there's been a lot of work done with the cancer cohort, putting in diagnostic images, pathology slides, other clinical data, written notes, and this can then be accessed under the strict criteria of the access review committee. It can be accessed by clinicians, researchers across the world. And we want our research library to be the premium source of that information and to have collaboration with researchers, clinicians, participants, worldwide, to speed up the generation of that information and those positive outcomes. It's a, a very, very rich data source now, and it'll only get bigger as we include people from the general population. Sharon Jones: That'd be amazing and have some quite incredible global, um, outcomes. Lisa? Lisa Beaton: I just had a little image actually pop into my head that I, I almost look at it a little bit like we're doing one of those, I think they might be called an "impossipuzzle" where actually we don't have the picture on the box, but we have lots and lots of little pieces that are all going in together and they're making up a really creative, wonderful, fantastic, woven story, a tapestry as you were, of different information that's coming through. And how incredible, you know what, what a wonderful legacy we're building, you know, and this amazing picture that's going to evolve and change and develop over the years to come. Sharon Jones: That's a wonderful note to end on, so we're going to wrap it up there. Thank you for listening. A special thanks to our guests, Kirsty, Frances, and Lisa, for joining me today as we discussed how lived experience can shape health research. If you'd like to hear more like this, please subscribe to the Behind the Genes on your favourite podcast app. And if you want to know more about the Participant Panel, you can head to the Genomics England website and listen to our 10-minute explainer podcast, Genomics 101. Behind the Genes is produced by Deanna Barac, Florence Cornish, Sophie McLachlan and Dave Howard at Bespoken Media.

According to NHS England, every maternity service in England will need to meet new clinical standards set out by the NHS to significantly reduce the number of women who die each year during or after pregnancy. This comes after figures published earlier this year showed a 20% increase in maternal deaths between 2022 to 2024 compared to rates from 2009 to 2011. More than 500,000 babies are born in England every year and to discuss what these announcements mean in practise for pregnant women, Anita Rani is joined by Michael Buchanan, BBC Social Affairs correspondent.At the age of nearly 40, BBC broadcaster Sophie Raworth thought she was too old to start running. She'd done no exercise for decades. But after being invited to take part in The Great North Run and then seeing a friend do the London Marathon, Sophie decided to give it a go. Although it didn't quite initially go to plan, she kept going on a path that would take her around the world, from Sydney to New York and the Sahara Desert, completing 20 marathons and 10 ultra-marathons. She tells Anita about her new book, Running On Air, and reveals how in running, she has discovered an unexpected strength, new confidence and great friendships. The Suzy Lamplugh Trust has published a report spotlighting the link between stalking and homicide to mark National Stalking Awareness week. They say there are huge gaps in recording stalking as a contributing factor to homicide and want to see further research on this. Anita is joined by Saskia Garner, Head of Policy and Campaigns at the Suzy Lamplugh Trust, and Detective Inspector Karen Butler from the Metropolitan Police, who works in the Stalking Threat Assessment Centre.On Monday, Sarah Finch became the European recipient of the Goldman Environmental Prize, for her work against oil drilling in Surrey, with the Weald Action Group. Their long legal battle led to a landmark judgement on fossil fuel emissions. The Goldman Prize, often referred to as the ‘Green Nobel', honours grassroots environmental activists from around the world. For the first time since its inception, all six prizes were won by women. Sarah joins Anita from California where the awards took place.Presenter: Anita Rani Producer: Andrea Kidd

NHS England's Federated Data Platform contract with Palantir Technologies must be torn up before it's too late. Palantir's NHS patient data contract is not a tool for improving healthcare, but the reverse. It is a vehicle for the further privatisation and militarisation of the NHS, designed to enrich a corporation whose ethics are fundamentally incompatible with public service. Subscribe! Donate! Join us in building a bright future for humanity! www.thecommunists.org www.lalkar.org www.redyouth.org Telegram: t.me/thecommunists Twitter: twitter.com/cpgbml Soundcloud: @proletarianradio Rumble: rumble.com/c/theCommunists Odysee: odysee.com/@proletariantv:2 Facebook: www.facebook.com/cpgbml Online Shop: https://shop.thecommunists.org/ Education Program: https://thecommunists.org/education-programme/ Each one teach one! www.londonworker.org/education-programme/ Join the struggle www.thecommunists.org/join/ Donate: www.thecommunists.org/donate/

Today is primary school offer day in England and Wales, when parents will be finding out where their children might be starting school in September. A new government-backed campaign has been launched to help parents and carers as figures show that over a third of children are currently starting reception without the basic skills they need for the classroom. Datshiane Navanayagam is joined by BBC Education reporter Kate McGough and Felicity Gillespie from children's charity Kindred Squared, to talk about what parents and carers need to know.The singer-songwriter Jessie Ware's new album, Superbloom, was released this week. As well as being known for her music, Jessie's family's passion for food led to the weekly podcast Table Manners, that she co-hosts with her mother Lennie, featuring celebrity guests like Ed Sheeran and Kylie. Jessie joins Datshiane to talk about her new album inspired by disco and funk and how she became more confident in her 40s.Autism Central is an online support service for the parents and carers of autistic people. Set up by NHS England in 2021, it has now been expanded to offer help for everyone in the support network of autistic people, including grandparents, partners, friends, and adult siblings. It's paid for by NHS England and run by the mental health charity Anna Freud. With growing numbers being diagnosed with autism - and waiting for a diagnosis - what can this type of online help offer? Datshiane is joined by Victoria Jackson who has been using the service, and Dr Georgia Pavlopoulou, Director of Autism Central at Anna Freud.Katriona O'Sullivan's childhood was marked by extreme poverty, neglect, addiction and abuse. She became pregnant at 15 and experienced homelessness, but went on to become an award‑winning academic and bestselling author, with her memoir Poor adapted for the stage. Katriona's new book, Hungry, explores her lifelong struggles with her body and the unrelenting drive to feel, “enough”. Katriona talks to Datshiane about how trauma, class and gender shape how women see themselves. Presenter: Datshiane Navanayagam Producer: Rebecca Myatt

PM admits government can't help on it's own as amid warnings energy shock will be worse than the 1970s, millions of drivers in line for £830 compensation from car finance scandal, and Sir Jim Mackey, Chief Exec of NHS England comes in to take your calls.

The UK was once a world leader in heart and lung transplantation. Pioneering surgeons attracted patients from all over the world. But the NHS has not kept pace with medical and technological developments and today the UK lags far behind most similar countries. It carries out fewer transplants and a lack of resources mean it doesn't routinely use modern technologies. Many of the health service's leading surgeons have left to work overseas in recent years, frustrated, they say, at the lack of attention transplant services have received from NHS England. Through speaking to patients, surgeons and experts, File on Four Investigates looks at what the UK needs to do to update and transform this life-changing service. Reporter Michael Buchanan Producers: Adam Eley & Paul Grant Technical Producer: Nicky Edwards Production Co-ordinator: Tim Fernley Editor: Tara McDermott

At the Royal College of Anaesthetists' Centre for Perioperative Care (CPOC) Perioperative Leads Day in London, host Andy Cumpstey speaks with James White, a perioperative medicine clinician (and qualified general practitioner) working within the NHS in Cheshire and Merseyside, serving as Clinical Lead for Perioperative Medicine and contributing to national improvement work with the Centre for Perioperative Care, Simon Rang, consultant anaesthetist at East Kent Hospitals University NHS Trust who also contributes to national healthcare improvement work including with the Centre for Perioperative Care, and Denny Levett, Director of the Centre for Perioperative Care, and a Professor of Perioperative Medicine and Critical Care and Consultant at University Hospital Southampton NHS Foundation Trust and the University of Southampton. The conversation covers how UK perioperative medicine policy is implemented through evolving NHS structures. They explain the relationship between national policy (Department of Health, NHS England) and delivery via regions, integrated care boards (ICBs), and local trusts, emphasizing integrated pathways spanning primary and secondary care, particularly post-COVID. James outlines five core requirements: early perioperative screening, proactive optimization/prehabilitation, maintaining health while waiting, listing patients only when medically fit, and shared decision-making. The guests discuss how regional and ICB networks share solutions, address variation and barriers (including finances and culture), and use CPOC guidance and resources alongside initiatives like GIRFT to support consistent implementation. -- Join us at Evidence Based Perioperative Medicine (EBPOM) World Congress 2026 in London. Be part of a global conversation as clinicians from around the world gather between 7-9th July at the British Library in London. Three days of evidence-based perioperative medicine, global insights, and expert debate—featuring speakers including Michael Marmot and Ken Rockwood. Register here - https://ebpom.org/product/ebpom-world-congress-2026/

Surgical quality is a term that is often thrown around in surgical practice. We have multiple quality improvement projects, metrics and benchmarks that motivate us to do better, and of course the ever expanding patient reviews to possibly “reflect” the type of surgical care provided. But what does quality actually mean? What metrics can we use to understand the type of care being provided by ourselves, our colleagues, and the health system at large. Today, we delve into these questions to understand how quality is currently understood within surgery and how we hope it to evolve in the future. Joining BTK fellow Agnes Premkumar and ASGBI hosts Jared Wohlgemut and Gita Lingam are two fantastic guests - Dr. Mark Cheetham, joining us from the UK, has deep experience in national audits and system-level quality improvement. Dr. Cheetham is a colorectal surgeon and the National Clinical Lead for General Surgery at the Getting it Right First Time Programme in NHS England, or GIRFT. Dr. Alexander Perez is representing the US; he is a board-certified general surgeon and minimally invasive surgeon at Baylor St. Luke's Medical Center. He has worked extensively with institutional quality programs and is the current assistant Dean for patient safety, simulation, and process improvement at the Baylor College of Medicine. Resources: Institute for Healthcare Improvement: https://www.ihi.org/library/tools/quality-improvement-essentials-toolkit NSQIP: https://www.facs.org/quality-programs/data-and-registries/acs-nsqip/ Getting it right first time (UK): https://gettingitrightfirsttime.co.uk/ ***Fellowship Application Link: https://forms.gle/QSUrR2GWHDZ1MmWC6Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium:General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

AI is transforming the world—but is it transforming privacy for better or for risk? We trust our GP with our deepest secrets, but can we extend that same trust to AI-powered systems and cloud-based suppliers? And if AI can re-identify people even in anonymized research data, is “anonymous” still real anymore? In this episode, Punit Bhatia and Tania Palmariellodiviney reveals how AI tools reshape confidentiality, integrity, availability, cloud sprawl, supplier risk, clinical transcription accuracy, re-identification, and even personal fears like voice-based deepfakes. The voice of experience rings clear: digital trust isn't a checkbox…it's engineered early with transparency, responsible data use, privacy by design, and safety by design. 

The four-year Cass Review, carried out for NHS England recommends limiting the use of puberty blockers to research settings. 

AI is transforming the world—but is it transforming privacy for better or for risk? We trust our GP with our deepest secrets, but can we extend that same trust to AI-powered systems and cloud-based suppliers? And if AI can re-identify people even in anonymized research data, is “anonymous” still real anymore? In this episode, Punit Bhatia and Tania Palmariellodiviney reveals how AI tools reshape confidentiality, integrity, availability, cloud sprawl, supplier risk, clinical transcription accuracy, re-identification, and even personal fears like voice-based deepfakes. The voice of experience rings clear: digital trust isn't a checkbox…it's engineered early with transparency, responsible data use, privacy by design, and safety by design. 

Risky Business returns for 2026! Patrick Gray and Adam Boileau talk through the week's cybersecurity news, including: Santa brings hackers MongoDB memory leaks for Christmas Vercel pays out a million bucks to improve its React2Shell WAF defences 39C3 delivers; the pink Power Ranger deletes nazis, while a catgirl ruins GnuPG Cambodian scam compound kingpin gets extradited to China, and we don't think it'll go well for him Krebs picks apart the Kimwolf botnet and residential proxy networks So many healthcare data leaks that we have a roundup section This week's episode is sponsored by Airlock Digital. The founders of the application allow-listing vendor, David Cottingham and Daniel Schell, discuss Microsoft's ClickOnce .NET app packaging, and how attackers have been abusing it to load code. Airlock hates it when you load code! This episode is also available on Youtube. Show notes US, Australia say ‘MongoBleed' bug being exploited | The Record from Recorded Future News Merry Christmas Day! Have a MongoDB security incident. | by Kevin Beaumont | Dec, 2025 | DoublePulsar Inside Vercel's sleep-deprived race to contain React2Shell | CyberScoop gpg.fail Hacktivist deletes white supremacist websites live onstage during hacker conference | TechCrunch Chinese attackers exploiting zero-day to target Cisco email security products | The Record from Recorded Future News Ni8mare  -  Unauthenticated Remote Code Execution in n8n (CVE-2026-21858) | Cyera Research Labs ServiceNow patches critical AI platform flaw that could allow user impersonation | CyberScoop Alleged cyber scam kingpin arrested, extradited to China | The Record from Recorded Future News FCC IoT labeling program loses lead company after China probe | Cybersecurity Dive Trump picks Lt. Gen. Joshua Rudd to lead NSA spy agency - The Washington Post NSA cyber directorate gets new acting leadership | The Record from Recorded Future News Dutch court sentences hacker who used port systems to smuggle cocaine to 7 years | The Record from Recorded Future News ECLI:NL:GHAMS:2026:22, Amsterdam Court of Appeal, 23-003218-22 The Kimwolf Botnet is Stalking Your Local Network – Krebs on Security Who Benefited from the Aisuru and Kimwolf Botnets? – Krebs on Security Coupang recovers smashed laptop that alleged data leaker threw into river | The Record from Recorded Future News Ransomware responders plead guilty to using ALPHV in attacks on US organizations | The Record from Recorded Future News Nearly 480,000 impacted by Covenant Health data breach | The Record from Recorded Future News Illinois health department exposed over 700,000 residents' personal data for years | TechCrunch Tech provider for NHS England confirms data breach | TechCrunch Hacker claiming to be behind ManageMyHealth breach: ‘I do it for the money and I'm in negotiations to get it' - NZ Herald